Novel Methods to Access Bioactive Molecules by Walsh, Anthony
University of Huddersfield Repository
Walsh, Anthony
Novel Methods to Access Bioactive Molecules
Original Citation
Walsh, Anthony (2015) Novel Methods to Access Bioactive Molecules. Doctoral thesis, University 
of Huddersfield. 
This version is available at http://eprints.hud.ac.uk/26947/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not-for-profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
 
 
 
 
 
 
 
NOVEL METHODS TO ACCESS BIOACTIVE 
MOLECULES 
 
 
 
ANTHONY EDMOND JUDE WALSH 
 
 
 
 
A thesis submitted to the University of Huddersfield in partial fulfilment of the requirements 
for the degree of Doctor of Philosophy 
 
The University of Huddersfield  
 
  19th November 2015 
  
1 
 
Copyright statement 
i. The author of this thesis (including any appendices and/or schedules to this 
thesis) owns any copyright in it (the “Copyright”) and he has given The 
University of Huddersfield the right to use such copyright for any administrative, 
promotional, educational and/or teaching purposes. 
ii. Copies of this thesis, either in full or in extracts, may be made only in accordance 
with the regulations of the University Library. Details of these regulations may be 
obtained from the Librarian. This page must form part of any such copies made. 
iii. The ownership of any patents, designs, trademarks and any and all other 
intellectual property rights except for the Copyright (the “Intellectual Property 
Rights”) and any reproductions of copyright works, for example graphs and 
tables (“Reproductions”), which may be described in this thesis, may not be 
owned by the author and may be owned by third parties. Such Intellectual 
Property Rights and Reproductions  cannot and must not be made available for 
use without the prior written permission of the owner(s) of the relevant 
Intellectual Property Rights and/or Reproductions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 
 
Acknowledgements  
 
 First I would like to thank my supervisor, Prof. Joe Sweeney. Joe has been a tremendous 
advisor; he’s been my harshest critic and my best advocate and I’ve learned an incredible 
amount under his mentorship. I’m grateful to him for believing in my potential and for 
encouraging me throughout. 
 
I'd also like to thank my secondary advisor during my time at Reading University, Dr. David 
Lindsay. David wasn't just an excellent chemist and teacher, he was also a good friend who 
introduced me to some of the finer restaurants in Reading as well as the excellent quality of 
Tebay Farmshop services. I also have him to 'thank' for my subsequent black coffee 
addiction.  
 
I worked with a talented bunch of people in the Sweeney group so thanks to Jim, Scarlet, 
James, Chris, Lucy, Kirsty, Sam, Ian, and Tes for making my PhD a little easier. I'd 
especially like to thank Tes for proof reading the first draft of this thesis. Outside the group 
I'd also like to thank Georgina and Kat for their infectious enthusiasm and many well earned 
coffees.   
 
There have been a lot of support staff without whom my research simply would not have 
been possible, but I'd like to single out Jim Rooney for his can do attitude and superhuman 
ability to problem solve whatever equipment issue I was having that day.   
 
Finally I want to thank my parents. Without their endless love, support and encouragement 
I would never have made it this far. So I’d like to dedicate this thesis to my Mum and Dad, 
who are still my greatest inspiration.  
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract  
 
This thesis is divided into two chapters detailing research on applying microwave 
methodology to access aminated nucleosides in significantly reduced time frames, and 
applying the Belluš-Claisen reaction to produce non-proteogenic dipeptides.  
 
1. Amination of Nucleosides Using Microwave Methodology  
 
2,2’-Anhydrouridine undergoes a ring opening reaction with aliphatic amines to give the 
corresponding aminated product. Under conventional heating reaction times are extremely 
lengthy, taking at least 3 to 4 days and up to a month in the case of very hindered amines. 
A modified procedure using microwave irradiation has proven to drastically reduce reaction 
time and has allowed access to novel nucleosides on gram scale. 
   
 
 
2. Functionalised Amino Acids via the Belluš-Claisen Rearrangement  
  
The Belluš-Claisen reaction is a [3,3] sigmatropic rearrangement of allylic amines, ethers 
and thioethers to give the corresponding amide, ester of thioester. A modified procedure of 
the Belluš-Claisen rearrangement was used to prepare functionalised dipeptides by reaction 
of a ketene prepared from N-phthaloylglycyl chloride in situ with allylic amino acid 
derivatives in the presence of a Lewis Acid and diisopropylethylamine. Rearrangments were 
successfully carried out using N,N-diallyl alanine and N-allyl proline. A range of N-allyl 
proline derivatives are demonstrated. However, attempts to repeat the reaction with 
structurally more complex amino acids did not result in successful reactions. 
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1. Amination of Nucleosides Using Microwave 
Methodology  
 
1.1 Introduction  
 
1.1.1 Nucleoside Chemistry  
 
Nucleoside chemistry dates back to 1869 when Miescher discovered a substance that he 
termed "nuclein".1  Twenty years later, Altmann isolated a protein-free nuclein which 
was termed "nucleic acid".2 Studies in this area continued but since the 1950s, 
nucleosides and nucleotides have been the subject of a wealth of research when their 
role in cells was established, most famously as the chemical building blocks of 
ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) chains.3  
 
A nucleotide is comprised of three components (Figure 1):-  A nitrogen-containing base which is either:- 
1. a purine, 1-2, a six-membered pyrimidine ring fused to a five membered 
imidazole ring 
         or 
2. a pyrimidine, 3-5,  a six membered heterocyle with two nitrogens in the 
ring.   A pentose sugar. In RNA this is ribose 6 and in DNA it is deoxyribose 7.  
Arabinose 8 and ribose 6 differ from the relative stereochemistry of the hydroxyl 
group in the C2’ position.  A phosphate group.4  
 
 13 
 
 
Figure 1: Nucleoside Structure2 
 
 
In 1953, using experimental data obtained by Wilkins and Franklin5, Watson and Crick 
determined that DNA exists as a double helix.6 DNA consists of two polynucleotide chains 
that are held together by hydrogen bonds between the paired bases (Figures 1 and 2). A 
(adenine 1) bases are paired with T (thymine 5) bases and C (Cytosine 3) are paired 
with G (guanine 2). The nucleotides are linked by a phosphodiester bond whereby the 5’ 
phosphate group of one nucleotide is linked to the 3’-OH group of another.4,6 
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Figure 2: Schematic model of the double helix (Copied with permission from Pray (2008)7 
 
Nucleoside molecules contain several functional groups within their structure that can be 
easily modified by chemical transformations.8 These modified nucleosides have been 
shown to possess a variety of biological and clinical properties. They mimic physiological 
nucleosides and can inhibit DNA synthesis causing chain termination which results in cell 
death.9  Over the years, numerous modified nucleosides have been used as antiviral, 
antibiotic and antitumor drugs.3,9,10 De Clerq  affirms that several anti-viral drugs had 
been developed including some used to treat HIV (human immunodeficiency virus).11,12 
The majority of research pertaining to nucleoside drugs relates to modified heterocyclic 
components but ribose core modification can lead to advanced biological activity.13 
Examples include the arabino-configured nucleosides (or ara-nucleosides): Cytarabine 
(1-ȕ-D-arabinofuranosylcytosine, ara-C) 9, Fludarabine (9-(β-D-Arabinofuranosyl)-2-
fluoro-9H-purin-6-amine) 10 and Clevudine (1-[2-deoxy-2-fluoro-β-arabinofuranosyl] 
thymine) 11.   
 
Cytarabine (Ara-C) 9 (Figure 3) consists of a cytosine base combined with an arabinose 
sugar. Ara-C 9 was first synthesized in 1959 and since that time it has proven to be a 
very effective drug in the treatment of non-Hodgkin lymphomas, acute myeloid  
leukaemias and as an antiviral drug eg to treat the herpes virus.14,15,16 
 15 
 
   
Cytarabine 15                                         Fludarabine 17                                 Clevudine 18 
 
Figure 3: Arabino Nucleosides 
 
Ara-nucleosides are isomeric with ribosyl derivatives but the 2’ position of the sugar 
moiety is epimeric. Thus, they have similar chemical properties to deoxyribosyl 
derivatives. This is a significant factor in their ability to inhibit DNA synthesis.15. In order 
to be effective, after Ara-C 9 has entered a cell, it must be metabolised to Ara-CTP 12, 
(1-β-D-arabinofuranosylcytosine triphosphate) (Figure 4) to become biologically active.14  
Once incorporated into a DNA strands Ara-CTP 12 causes chain termination, resulting in 
a block of DNA synthesis and subsequent cell death.19  
 
Figure 4: Ara-CTP10 
 
The success of Ara-C (cytarabine) 9 in treating acute leukaemias prompted the 
development of further nucleoside analogues, such as fludarabine 10 (Figure 3). 
Fludarabine 10 is widely used in the treatment of chronic lymphocytic leukaemia and 
non-Hodgkins lymphoma.20,21 Fludarabine 10 must be converted to F-ara-ATP 13 once it 
is in the cell if it is to be effective. Studies have shown that F-ara-ATP 13 inhibits DNA 
synthesis and also stalls RNA translation.22  
 
 
Figure 5: F-Ara-ATP  
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Clevudine 11 (Figure 3), a pyrimidine L-nucleoside analogue, has proven to have potent 
activity against HBV.23 Hepatitis B virus (HBV) infection affects more than 350 million 
people in the world. It is estimated that over half a million deaths per year are as a 
result of HBV complications.24 In general, nucleoside inhibitors interfere with the viral 
activities by incorporation into DNA chains and competitive inhibition. However, in 
clinical trials, it was noted that Clevudine was not incorporated into DNA as anticipated.25 
Clevudine inhibits DNA non-competitively by binding to the Hepatitis B Virus active site 
and thus altering the viral structure.26,27  
 
In addition to their therapeutic uses, modified nucleosides are useful as the chemical 
starting points for functional polynucleotides.28 As part of an ongoing research program 
on novel catalytic polynucleotides, a synthetic entry to isocytosines 14, arabino-
configured analogues of the tRNA nucleoside Lysidine 15 (Figure 6), was required. 
Polynucleotides, resulting from monomers that are similar to 14, have been shown to 
form stable duplexes with DNA containing isoguanosine.29 Further, related isocytosines 
have been reported to  possess anti-tumour properties.30  
  
Figure 6: Lysidine tRNA nucleobase 
 
Existing methods to obtain compounds 14 have proven to be lengthy and often low-
yielding. The ring-opening of 2,2’-O-anhydrouridine 16 by ammonia was first reported 
by Todd et al31  (Scheme 1).  
     
Scheme 1: Ring opening of 2,2’-O-anhydrouridine with ammonia31 
 
The method was later refined and generalized to include higher amines.32 The time 
required to give the aminated derivatives 14 is very slow, taking at least 3 to 4 days and 
up to a month in the case of very hindered amines such as cyclohexyl amine. We hoped 
to produce a more time efficient method of accessing aminated arabinose-
anhydrouridines by utilizing microwave technology. 
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1.1.2 Microwave Chemistry  
1.1.2.1 Introduction to Microwaves 
 
Microwave technology has been used in inorganic chemistry since the late 1970s.33 
However, it did not gain widespread acceptance in organic laboratories until the late 
1980s. The availability of microwave technology and its adoption in organic chemistry 
has been relatively slow compared to other fields, for example computational and 
combinatorial chemistry.34 This slow uptake could be attributed to safety aspects and 
issues with control and reproducibility.35 Since the mid-1990s the number of publications 
in this field has considerably increased.36 This development is mainly due to the shorter 
reaction times afforded by microwave chemistry as well as the availability of improved 
equipment which included redesigned microwave cavities to improve the heating 
characteristics.34,33 A correctly designed cavity will enable uniform heating because cold 
and hot spots will be eliminated. This is particularly important for organic chemistry 
because it means that the heating of small samples can be accurately controlled.37  
 
Microwave heating possesses certain advantages over conventional heating:   Energy is imparted directly to the solvent and sample, rather than via 
conduction through the reaction vessel; thus, heating is quicker.  A correctly designed reactor allows a uniform increase in temperature.  It is possible to increase the temperature above the boiling point of the 
solvent, thus solvents with lower boiling points can be used if desired.  Microwave heating is more energy efficient.38,39 
 
1.1.2.2 Microwave Theory 
 
All electromagnetic radiation can be divided into two components: an electric field and a 
magnetic field. The microwave electric field is responsible for the dielectric heating 
phenomenon that allows microwave oven technology to function. Dielectric heating 
occurs using two principal mechanisms, dipolar polarization and conduction. 
 
The first mechanism is dipolar polarization. This is the mechanism most commonly 
associated with microwave heating. Only substances that contain a dipole moment will 
generate heat when irradiated with microwaves. Dipoles respond to external electric 
fields and will rotate and try to align themselves with the electric field.34 When an 
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external electric field provides the energy for this rotation, any molecules that contain a 
dipole will attempt to align themselves with it. The speed with which a molecule will do 
so depends on the environment. Instantaneous alignment is hindered in liquids due to 
the proximity of other molecules, causing a transfer of kinetic energy. Conversely, 
molecules in gases will align rapidly because their molecules are not in such close 
proximity and thus do not adversely affect the alignment. Gases are therefore not 
heated as efficiently as liquids within the microwave environment. In most regions of the 
electromagnetic spectrum, the ability to impart energy via the dielectric effect is limited. 
Low frequency radiation will allow molecules to rotate in alignment with the field, but the 
heating effect is small. In high frequency radiation there is insufficient time for the 
molecules to rotate. As the heating is dependent on motion being parted into the 
component molecules of a material, there is therefore no change in temperature.  
 
Microwave radiation is unique in being between these two extremes. Microwave radiation 
is not so high that dipoles do not have time to respond to the electric current. The 
frequency is not, however, low enough for dipoles to fully align before the orientation of 
the field changes. This creates a phase difference between the orientation of the field 
and the dipole. This phase difference causes energy to be lost from the dipole by 
molecular friction and collisions, giving rise to dielectric heating.34  
 
If two samples, one containing water and the other dioxane, were irradiated for a fixed 
time at a fixed power, the sample of water would have a higher temperature at the end 
of the experiment. Dioxane, as a non-polar solvent, lacks the dipole characteristics 
necessary for microwave dielectric heating so energy can not be transferred to the 
sample. However, if two samples containing water, one with tap water, the other distilled 
water, were used in the same experiment they would not heat uniformly. The sample 
containing the tap water would be hotter which can be explained by conduction, the 
second principal mechanism.34 
 
When a solution is subjected to an electric field, any ions will be influenced by the field 
and will move and collide. Due to the increased collision rate this causes, a greater 
conversion of kinetic energy to heat will result. Heat generated via the conductivity is 
much stronger than that generated solely by dielectric heating. This explains the 
difference in temperature mentioned above. The sample containing tap water will reach 
a higher temperature than pure water because the ions, influenced by conduction, will 
add to the heat produced. 
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Dielectric heating is dependent on dipole rotation and therefore, it should follow that the 
higher the solvent dielectric constant (i.e. the more polar a solvent is), the more 
effective it will be as a solvent for microwave heating. It is possible for two solvents with 
comparable dielectric constants to have significant differences as microwave solvents.  
Factors that affect this are the efficiency of a solvent to convert energy into heat, the 
volume of the reaction and the geometry of the reaction vessel. These latter two are 
vital in order to create reproducible and uniform heating but volume is the more 
significant factor.  It is important to follow manufacturer guidelines because over or 
under loading the vessel can result in difficulty obtaining reproducible results.34 
 
1.1.2.3 Microwaves and the Effect on the Speed of Reaction. 
 
The major advantage in employing microwave methodology is a decrease in required 
reaction time.40 How microwave irradiation alters the outcome of organic synthetic 
reactions has been the subject of debate.41,42 Specifically, whether it is simply a thermal 
effect or if there is something unique to microwave reactions and if any non-thermal 
effects should also be considered. There is some controversy around the effects of the 
magnetic field but in most cases of microwave reactions in the literature, the decrease in 
reaction time can be attributed solely to thermal effects.34,43   
 
In well-designed systems, microwave heating is efficient, uniform and rapid which can 
lead to different reaction profiles when compared to conventional heating, even if the 
final temperature is the same. The first published examples of microwave assisted 
organic synthetic chemistry made use of domestic ovens and it is only recently that  
purpose-built machines have become available. While domestic ovens have the 
advantage that they are widely available and relatively cheap there are usually major 
safety concerns with safety, especially when using pressurised vessels.34  
 
A desire to increase safety led to the development of a number of reflux systems which 
all broadly have the same advantages and disadvantages. These systems are safer to 
use and there is minimal risk of an explosion because reactions are performed at 
atmospheric pressure and flammable products cannot enter the cavity. However, 
because the reactions are performed at atmospheric pressure, this means that the 
temperature can only be increased a few degrees (13˚C to 26˚C),  above the boiling 
point of the solvent being used.  This higher temperature will speed up the reaction to 
some degree but it does not utilise the full potential of microwave heating.34 Ideally, 
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reactions will be performed under pressure in a microwave cavity so that they will 
benefit both from rapid heating rates and remote dielectric microwave heating. Modern 
apparatus, purpose built for running these reactions, are safe, have good temperature 
control and accurate pressure measurement.43 
 
We therefore planned to apply pressurized microwave system methodology to the 
amination of anhydrouridine. We hoped that the reaction accelerating effects would 
drastically reduce the reaction time without the need for harsh conditions. It was also 
envisaged that this would ease the purification of the product because there would be 
limited or no side reactions with the reagents and conditions employed. 
 
1.1.3 Aminated Nucleosides  
 
During the 1950s and 1960s, numerous studies were reported relating to the ring 
opening of 2,2’-anhydronucleosides by nucleophiles but the procedures reported were 
lengthy and sometimes required harsh conditions.44,29,45,46 There are literature 
investigations into nucleophilic attack of ammonia,31,32 sulfides31,47 and halides.48 Amines 
attack at the 2-position (Scheme 1) giving the corresponding 2-aminated product. 
Conversely, azides will ring open by attacking at the 2’ position. For example, azidation 
of 2,2’-anhydrouridine 16 will give 2’-azido-2’-deoxyuridine 18 in one step (Scheme 
2).49 
 
 
   
Scheme 2: Azidation of 2,2-anhydrouridine49 
 
It is possible to access 2’-aminated nucleosides by the formation of intermediate azides 
that can be later reduced to the corresponding amine49,50. Wnuk et al.51 developed a 
scheme to give the 2’-amino-2’-deoxyuridine 19 in a two-step process (Scheme 3). 
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Scheme 3: Synthesis of 2’-amino-2’-deoxyuridine51 
 
Delia and Beranek44 reported the reaction of 2,2’-anhydrouridine 16 with ammonia, 
primary aliphatic amines, secondary aliphatic amines and aromatic amines. Their work 
proved successful with ammonia and primary amines, leading to the corresponding 2-
aminated nucleosides 20 (Scheme 4 and Table 1).  
 
     
Scheme 4: Synthesis of 2-aminated nucleosides  
 
Table 1: Conventional amination reaction times44 
 
Entry R % Yield Time of Reaction (Hours) 
1 n-Bu 82 72 
2 Allyl 86 96 
3 Benzyl 90 360 
4 Cyclohexyl 72 768 
5 Ph 0 - 
 
 
Aromatic amines (Scheme 4, Table 1, Entry 5) failed to aminate the nucleoside because 
they were not sufficiently nucleophilic to effect the reaction under the conditions 
employed. Secondary amines also only returned starting materials when used. It had 
been assumed that these would successfully react as they had base strengths similar to 
the primary amines. The lack of reactivity was presumably due to steric issues. Evidence  
to support this was the relative rates of reaction of the various primary amines. Butyl 
amine and allyl amine both reacted relatively quickly (three and four days respectively) 
while the more bulky cyclohexylamine and benzylamine took considerably longer (almost 
a month). These results demonstrate a significant steric dependence as the branching  
 22 
 
 
increases. It was later reported that some secondary amines were successful in opening 
the 2,2’-O-anhydo-bridge of compounds containing the 3’-O-mesyl group, for example 
the mesyl protected compound 21 reacted with piperdine to give the 2-aminated product 
22. However, this also resulted in an epoxide ring forming between the 2’ and 3’ 
positions (Scheme 5).52 
 
 
Scheme 5: 2,2’-O-Anhydro-bridge opening with piperidine52 
 
 
1.1.4 Amination of 2,2'-anhydroarabinouridine (23) and its 
Derivatives  
 
As part of a research program directed towards novel catalytic polynucleotides, 
Ochocińska53 had attempted to apply microwave methodology to the same chemistry 
(Scheme 6, Table 2) in the hope of cutting the time required to access C2-amine-
substituted nucleosides.    
 
 
Scheme 6: Initial amination reaction conditions53 
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Table 2: Initial Reactions investigated by Ochocińska53 
 
Entry Reagents Temp (˚C) Time 
(mins) 
R R1 R2 Product, 
Yield % 
1 Benzophenone 
imine 
120 60 C(Ph)2 TBS OH Trace 
2 MeNH2 120 30 Me TBS OH Partial 30, 
not isolated 
3 MeNH2 80 60 Me TBS TBS 30, 65  
4 MeNH2 80 60 Me TBS OH 30, 89  
5 MeNH2 80 60 Me TBS TBS 0 
6 1)Zinc 
2)NH2Me 
120 60 Me TBS TBS 0 
7 NH2Me 
BF3.Et2O 
80 30 Me OH OH 0 
 
When 5’-O-tert-butyldimethylsilyl-2,2’-anhydrouridine was reacted with methylamine 
using microwave irradiation at 120˚C for 30 minutes, a mixture of products was 
obtained. 1H NMR analysis of the crude mixture revealed that some of the expected 
product 24 was present (Entry 2). Several different temperature and reaction times 
were tried. It was found that 80˚C for 1 hour (Entry 4) gave the expected product 24 in 
89% yield. Of particular satisfaction was that to isolate the product as a colourless solid, 
only concentration of the reaction mixture followed by filtration was required. Addition of 
a Lewis acid or other modifications of initial conditions failed to give the desired product. 
 
The purpose of this research was to follow up this lead to devise a general protocol for 2-
amination of ara-uridines.  
 
1.2 Results and Discussion 
 
5’-O Protected 2,2'-anhydrouridine of general structure 23 (Scheme 6) are readily 
prepared and have served as key intermediates in this research. It was necessary to 
optimise the synthesis of the starting materials at this point. We wanted to conduct the 
experiments on a gram scale reactions and the method used did not give sufficient 
starting materials for the reaction. 
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The procedure outlined by Ochocinska53 was followed and this gave the desired 2,2’-
anhydrouridine 16. (Scheme 7) 
 
Scheme 7: Synthesis of 2,2’-anhydrouridine53 
 
Purification by recrystallization in methanol proved difficult because the product was only 
sparingly soluble and a large excess of methanol was needed to completely dissolve the 
solution. It was found that simply washing the crude product with cold methanol resulted 
in a product that was found to be pure by 1H NMR analysis.  
 
When attempting to repeat the TBS protection step a mixture of both the mono and di-
protected compound 27 and 28 were obtained.  
 
 
Scheme 8: TBS Protection of 2,2’-anhydrouridine53 
 
Crude 1H NMR analysis showed mono-protected compound was the major product 
(20:80 ratio) but separation of the two compounds during the column chromatography 
purification step proved challenging. This meant that the mono-protected compound was 
isolated with yields of only 5-21%.  
 
The di-TBS protected compound was also challenging to purify, giving a yield of 65% 
(Table 2, Entry 3), therefore alternative silyl protecting groups were investigated to 
determine if this would simplify the purification.  
 
Silyl ethers are widely used protective groups for hydroxyl functional groups because 
they are stable under a wide range of conditions and are removable with high 
selectivity.54,55 Their reactivity can be modulated by carefully selecting the substituents 
on the silicon atom.56,57 Originally TBS had been used because it is a very widely used 
silyl protective group.58,59 It can be introduced with several reagents and can be easily 
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removed under conditions that do not affect other functional groups.57 It is sensitive 
toward acid but is stable toward base and it can withstand temperatures up to 230˚C.60 
The TBDPS group is far more stable than the TBS group toward acid but is less stable 
than the TBS group towards base. The TBDPS group has also proven to have better 
stability to many reagents which are not compatible with the TBS group.57,61  
 
1.2.1 Optimization of Protection Step 
 
In order to improve the selectivity of the protection step of the starting material the TBS 
protecting group was changed to the TBDPS group. Following a procedure by Sebesta et 
al.62  (Scheme 9), the primary alcohol of 2,2’-anhydrouridine 16 was protected with 
TBDPS-Cl to give the TBDPS protected compound 29. 
 
   
Scheme 9: Synthesis of 5’-O protected 2,2’-Anhydrouridine  
 
Analysis of the crude residue by 1H NMR spectroscopy showed that only the mono-
protected compound 29 was obtained, which made the resulting purification by column 
chromatography straightforward. 
 
5’-O-TBDPS-2,2’-anhydrouridine 29 was reacted with a variety of amines on 100 mg 
scale (Scheme 10) using the previously optimised microwave methodology conditions 
(Scheme 6, Table 2, Entry 4). 5’-O-TBDPS-2,2’-anhydrouridine 29 was successfully 
reacted with a range of primary amines to give compound 30 in yields of 73-51% 
(Scheme 10 and Table 3). Secondary amines failed to give the desired product, returning 
the amine and compound 29. 
 
 
Scheme 10: Amination of TBDPS protected 2,2’-Anhydrouridine  
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Table 3. Amination of 5’-O-TBDPS-2,2’-Anhydrouridine 
Entry Compound R % Yield 
1 30a Me 73 
2 30b Et 65 
3 30c Pr 73 
4 30d n-Bu 68 
5 30e sec-Bu 64 
6 30f Allyl 66 
7 30g n-Pentyl 61 
8 30h n-Hexyl 52 
9 30i Benzyl 56 
10 30j Cyclohexyl 51 
11 30k iso-Pentyl 58 
12* 30d n-Bu 74 
13 30l iso-Pr 0 
14 30m iso-Bu 0 
15 30n tert-Bu 0 
16 30o 2-Ethyl-hexyl 0 
17 30p Ph 0 
18** 30b Et 0 
conditions: *rt, 4 days **reflux, 1 hr 
 
 
This compares very favourably with amination using conventional methods. When using 
primary aliphatic amines, this gave a very significant reduction in reaction time 
compared to similar reactions reported in the literature (Compare Table 1, Entries 1-4 
with Table 3, Entries 4, 6, 9 and 10). The reaction was repeated conventionally, being 
left to stir at room temperature until the starting material was consumed as monitored 
by TLC analysis (Table 3, Entry 12). This took four days to go to completion, compared 
to 1 hour with microwave heating (Table 3, Entry 4). The reaction was also repeated 
using a conventional hot plate for heating. After being refluxed in THF for one hour, TLC  
analysis showed that there was no conversion of starting material (Table 3, Entry 18). It 
took four days for unprotected 2,2'-anhydrouridine 16 to undergo the same reaction 
(Table 1, Entry 1), thus the decrease in reaction time can be explained solely by the 
application of microwave irradiation.  
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1.2.2 Amenity To Larger Scale Reactions 
 
The reaction was repeated on a one gram scale using n-butyl amine in 10 ml of THF 
using the standard conditions (1 hr, 80˚C, 300 W) but on a 1g scale. When first 
attempted using butylamine the product had already started to precipitate at the end of 
the reaction. A final yield was obtained of 90%. Gratifyingly, this was not only a better 
yield than the 100 mg scale reaction, but also higher than when the reaction was carried 
out conventionally.44  
 
The reaction was then repeated on the same scale using the same amines that had 
successfully given aminated product 30 (Scheme 10). When attempting the reaction 
using cyclohexylamine on 1g scale, no improvement in yield was noted. This time the 
reaction mixture was concentrated in vacuo at 1mm pressure. Analysis of the crude 
residue by 1H NMR spectroscopy revealed that the reaction had not gone to completion. 
The reaction was repeated on the same scale, with twice the amine loading and double 
the reaction time. The reaction mixture was again concentrated under 1mm pressure 
and analysis of the solid residue revealed the remaining material was the 2-aminated 
product. The total yield obtained was 81%. Overall yields for 1g scale reactions ranged 
from 70-90% (Table 4). 
 
In summary, the reaction proceeded smoothly with simple and unhindered amines. As 
observed when performing the reaction under conventional conditions, increasing steric 
bulk had an adverse effect on the reaction. In the case of cyclo-hexylamine, twice the 
usual amine load was required and it was also necessary to double the reaction time in 
order to drive the reaction to completion. However, as the reaction is reported to take 
one month using conventional methods this still represents a significant improvement.  
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Table 4. Amination of 5’-O-TBDPS-2,2’-Anhydrouridine (1g scale) 
 
Entry Compound R % Yield 
1 30a Me 85 
2 30b Et 86 
3 30c Pr 88 
4 30d n-Bu 89 
5 30e iso-Bu 80 
6 30f Allyl 87 
7 30g Pentyl 85 
8 30h Hexyl 79 
9 30i Benzyl 70 
10 30j Cyclo-hexyl 81 
11 30k iso-pentyl 81 
 
 
1.3 Conclusions and Future Work 
 
We have reported a new method of aminating 2,2’-anhydrouridine using a microwave 
methodology. The presented methodology gave a new, effective, high yielding and neat 
way of obtaining 2-aminated nucleosides. This discovery offers a means to increase the 
capacity of these molecules and significantly decreases the required reaction time. 
 
1.4 Experimental 
 
Reagents were purchased from Sigma-Aldrich, Acros, Alfa Aesar or Fisher Scientific and 
were not purified except where stated.  Solvents were purchased anhydrous and stored 
over molecular sieves, or distilled under nitrogen from an appropriate drying agent.  THF 
and diethyl ether were distilled from sodium benzophenone ketyl radical while DCM and 
acetonitrile were distilled from calcium hydride. Thin layer chromatography was 
performed on aluminium sheets coated with Merck silica gel 60 F254 with visualisation 
using potassium permanganate solution and/or scrutinised under 254 nm UV light. 
Column chromatography was performed using Silica gel 60 (35-70 microns) supplied by 
Fisher.  
 
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker Advance 
400 NMR spectrometer (1H NMR at 400 MHz, 13C NMR at 100 MHz) with the appropriate 
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deuterated solvent.  Chemical shifts in 1H NMR spectra are expressed as ppm downfield 
from TMS and in 13C NMR, are relative to internal standard, and reported as singlet (s), 
doublet (d), triplet (t), quartet (q) and combinations thereof, or multiplet (m).  Coupling 
constants (J) are quoted in Hz and are rounded to the nearest 0.5 Hz.  Mass 
spectrometry was performed using a Bruker MicroTOF-Q instrument with electrospray 
ionisation in the positive mode.  FT-IR data was acquired using Thermo Electron 
Corporation Nicolet 380 FTIR with Smart Orbit diamond window instrument with 
wavenumbers being reported in cm-1.  All melting points were obtained using a Stuart 
SMP10 melting point instrument. All non-microwave reactions were carried out under an 
inert atmosphere of nitrogen that was dried by passage through phosphorus pentoxide. 
 
Microwave reactions were performed using a Milestone MicroSYNTH reactor and SK10 
vessel with or without three inserts that each contained one magnetic stirring bead 
depending on volume. Twist control, rotor control, start parameters and continuous 
power were all selected. T1 control was used with 60 % stirring.  
 
 
 
1.4.1 Numbering of atoms in a nucleoside molecule 
 
 
 
 
 
1.4.2  2,2’-Anhydrouridine 1663  
 
 
 
Uridine (13.0 g, 53.0 mmol) and diphenyl carbonate (13.0 g, 60.0 mmol) were slurried 
in DMF (30 mL) and the reaction was heated to 80 ˚C. After one hour the reagents had 
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dissolved and sodium hydrogen carbonate (0.53 g, 6.0 mmol) was added followed by 
heating the reaction to 120 ˚C. After stirring for five hours the reaction was allowed to 
cool to room temperature and the resulting precipitate was collected by filtration. The 
product was washed with MeOH to give the crude as a colourless solid. (9.71g, 42.9 
mmol, 81%), mp = 238-40 ˚C. lit 238-244 ˚C 
 H (400 MHz, DMSO-d6), 3.19 (1H, dd, J = 6.0, 11.5 Hz, C5’-H1), 3.28 (1H, dd, J = 5.0, 
11.5 Hz, C5’-H2), 4.08 (1H, app t, J = 5.0 Hz, C4-H’), 4.38-4.41 (1H, m, C3’-H), 5.00 
(1H, br s, C5’-OH), 5.20 (1H, app d, J = 6.0 Hz, C2’-H), 5.85 (1H, d, J = 7.5 Hz, C5-H), 
5.91 (1H, br s, C3’-OH), 6.30 (1H, d, J = 6.0 Hz, C1’-H), 7.84 (1H, d, J = 7.5 Hz, C4-H); C (100 MHz, DMSO-d6), 61.3 (C5’), 75.2 (C3’), 89.2 (C2’), 89.7(C4’), 90.5 (C1’), 109.1 
(C5), 137.3 (C4), 160.3 (C2), 171.7 (C6); max (thin film), 1650 (C=O); m/z calculated 
for C9H10N2O5 [M+Na]
+, 249.0482, found 249.0482. 
 
1.4.3 TBS Protection 
 
2,2’-Anhydrouridine (3.00 g, 13.3 mmol) was dissolved in pyridine (15 mL) at 0 oC. 
TBDPS chloride (3.64 g, 13.3 mol) was added drop-wise in pyridine (5 mL). After stirring 
for four days at room temperature, the reaction was treated with ether (30 mL) and the 
pyridinium salt was removed by filtration. After evaporating the solvents, the crude 
mixture was dissolved in DCM and washed with water to remove the remaining pyridine. 
Purification by flash chromatography MeOH:DCM (7.5:92.5) gave 5’-O-tert-
butyldimethylsilyl-2,2’-anhydrouridine (601 mg, 2.50 mmol, 19%), mp = 137-140 ˚C 
and 3’,5’-di-O-tert-butyldimethylsilyl-2,2’-anhydrouridine (611 mg, 1.34 mmol, 10%), 
mp = 100-102 ˚C, obtained as colourless solids. 
 
1.4.4 5’-O-tert-Butyldimethylsilyl-2,2’-anhydrouridine 27 
 
 
 H (400 MHz, DMSO-d6), -0.03 (3H, s, Si-CH3), -0.03 (3H, s, Si-CH3), 0.83 (9H, s, CCH3), 
3.39-3.52 (m, 2H, C5’-H1, C5’-H2), 4.09-4.12 (1H, m, C4’-H), 4.37 (1H, m, C3’-H), 5.26 
(1H, d, J = 5.5 Hz, C2’-H), 5.90 (1H, d, J = 7.5 Hz, C5-H), 6.00 (1H, d, J = 4.0 Hz, C3’-
OH), 6.33 (1H, d, J = 5.5 Hz, C1’-H), 7.47 (d, 1H, J = 7.5 Hz, C4-H); C (100 MHz, 
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DMSO-d6), -5.03 (Si-CH3), -5.01 (Si-CH3), 18.5 (SiC), 26.2 (Si(C)CH3), 62.7 (C5’), 74.5 
(C3’), 88.4 (C2’), 89.1 (C4’), 90.1 (C1’), 109.2 (C5), 137.3 (C4), 160.0 (C2), 171.4 
(C6); max (thin film),  1530 (C=N), 1651 (C=O), 2929 (C-H aliphatic); m/z calculated for 
C15H24N2O5Si [M+H]
+, 341.1527, found 341.1528. 
 
1.4.5 3’,5’-Di-O-tert-butyldimethylsilyl-2,2’-anhydrouridine 28 
 
 
 
 H (400 MHz, DMSO-d6), -0.04 (3H, s, Si-CH3), -0.03 (3H, s, Si-CH3), 0.15 (3H, s, Si-
CH3), 0.17 (3H, s, Si-CH3), 0.81 (9H, s, CCH3), 092 (9H, s, CCH3), 3.43 (dd, 1H, J = 5.5, 
11.5 Hz, C5’-H1), 3.55 (1H, dd, J = 5.0, 11.5 Hz, C5’-H2), 4.06 (1H, app dd, J = 5.0, 9.0 
Hz, C4’-H) 4.53 (1H, m, C3’-H), 5.26 (1H, dd, J = 1.0, 5.0 Hz, C2’-H), 5.90 (1H, d, J = 
7.5 Hz, C5-H), 6.33 (1H, d, J = 6.0 Hz, C1’-H), 7.47 (d, 1H, J = 7.5 Hz, C4-H); C (100 
MHz, DMSO-d6), -5.10 (Si-CH3), -5.07 (Si-CH3), -4.66 (Si-CH3), -4.50 (Si-CH3), 18.2 
(SiC), 18.4 (SiC),  26.0 (Si(C)CH3), 26.1 (Si(C)CH3), 61.7 (C5’), 76.0 (C3’), 87.4 (C4’), 
89.1 (C2’), 89.6 (C1’), 109.3 (C5), 137.2 (C4), 160.0 (C2), 171.3 (C6); max (thin film),  
1468 (C=N), 1656 (C=O), 2929 (C-H aliphatic); m/z  calculated for C21H38N2O5Si2 
[M+H]+, 455.2392, found 455.2393. 
 
1.4.6 5’-O-tert-Butyldiphenylsilyl-2,2’-anhydrouridine 2962  
 
 
2,2’-Anhydrouridine(3.00 g, 13.3 mmol) was dissolved in pyridine (26 mL) and DMF (12 
mL) at 0 oC. TBDPS chloride (3.64 g, 13.3 mol) was added dropwise over five minutes. 
After stirring for two days at room temperature DCM was added (70 mL) and washed 
with saturated NaHCO3 solution (3 x 50 mL). The organic layer was dried over Na2SO4, 
filtered and concentrated in vacuo to give the crude product. Purification by flash 
chromatography MeOH:DCM (0:100 to 20:80) gave the desired product as colourless 
crystals. (3.21g, 6.92 mmol, 52%), mp = 181-182˚C. 
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H (400 MHz, DMSO-d6), 0.92 (9H, s, CCH3), 3.47 (dd, 1H, J = 6.5, 11.5 Hz, C5’-H1), 
3.59 (dd, 1H, J = 5.0, 11.5 Hz, C5’-H2), 4.15-4.20 (1H, m, C4’-H), 4.43-4.47 (1H, m, 
C3’-H), 5.26 (1H, dd, J = 1.5, 5.5 Hz, C2’-H), 5.89 (1H, d, J = 7.5 Hz, C5’-H), 6.01 (1H, 
d, J = 4.5 Hz, C3’-OH), 6.33 (1H, d, J = 5.5 Hz, C1’-H), 7.37-7.49 (6H, m, Ar-H), 7.50-
7.58 (4H, m, Ar-H), 7.93 (d, 1H, J = 7.5 Hz, C4-H); C (100 MHz, DMSO-d6), 19.2 (SiC), 
26.9 (Si(C)CH3), 63.1 (C5’), 74.4 (C3’), 87.6 (C4’), 89.1 (C2’), 89.8 (C1’), 109.2 (C5), 
128.4 (Ar-C), 128.4 (Ar-C), 130.4 (Ar-C), 130.4 (Ar-C), 132.8 (Quat. Ar-C), 133.0 (Quat 
Ar-C), 135.4 (Ar-C), 135.4 (Ar-C), 137.3 (C4), 159.9 (C2), 171.4 (C6); max (thin film), 
1533 (C=N), 1650 (C=O), 2157, 2929 (C-H aliphatic); m/z calculated for C25H28N2O5Si 
[M+Na]+, 487.1660, found 487.1666. 
 
1.4.7 General Amination Procedure 
5’-O-TBDPS-2,2’-anhydrouridine (100 mg, 0.21 mmol, 1.0 eq) was dissolved in THF (0.5 
ml) and primary amine (10.0 eq). The mixture was reacted at 80 ˚C for 1 hour at 300W. 
After completion the reaction mixture was poured into a flask of ether (100 ml). 
Filtration of the resulting precipitate gave the product. 
 
1.4.8  3-((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)  
-3’, 4’-dihydroxyoxolan-2’-yl)-2-(methylamino)pyrimidin-6(1H)-
one 30a 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100 mg, 
0.21 mmol, 1.0 eq) and methylamine in 2.0M THF solution (1.05 mL, 2.1 mmol, 10.0 eq) 
3-((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-3’, 4’-dihydroxyoxolan-2’-yl)-
2-(methylamino)pyrimidin-6(1H)-one  was obtained as a colourless solid (76mg, 0.15 
mmol, 73%), mp = 187-188 ˚C. A drop of D2O was added to the analytical sample 
before the 1H NMR analysis. 
 H (400 MHz, DMSO-d6), 1.00 (9H, s, C(CH3)3), 2.71 (3H, s, N-CH3), 3.76-3.79 (1H, m, 
C4’-H), 3.81-3.84 (1H, m, C5’-H1), 3.92 (1H, dd, J = 3.0, 11.5 Hz, C5’-H2), 4.07 (1H, 
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app t, J = 6.5 Hz, C3’-H), 4.25 (1H, app t, J = 6.0 Hz, C2’-H), 5.26 (1H, d, J = 7.5 Hz, 
C5-H), 5.86 (1H, d, J = 6.0 Hz, C1’-H), 7.38-7.51 (6H, m, Ar-H), 7.58-7.68 (5H, m, Ar-
H, C4-H); C (100 MHz, DMSO-d6), 19.3 (Si-C(CH3)3), 27.0 (Si-C(CH3)3), 28.7 (N-CH3), 
62.9 (C5’), 74.6 (C3’), 75.9 (C2’), 82.9 (C4’), 85.9 (C1’), 104.9 (C5), 128.4 (Ar-C), 
128.4 (Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.5 
(Ar-C), 135.6 (Ar-C), 139.2 (C4), 153.6 (C2), 170.0 (C6); max (thin film), 3304 (N-H), 
1650 (C=O); m/z calculated for C26H33N3O5Si [M+H]
+, 496.2262, found 496.2267. 
 
1.4.9 3-((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-
3’,4’-dihydroxyoxolan-2’-yl)-2- (ethylamino)pyrimidin-6(1H)-one 
30b 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and ethylamine in 2.0M THF solution (1.05 mL, 2.1 mmol, 10.0 eq) 
3-((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-
2-(ethylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (71mg, 0.14 
mmol, 65%), mp = 193-194 ˚C. A drop of D2O was added to the analytical sample 
before the 1H NMR analysis. 
 H (400 MHz, DMSO-d6), 0.99 (9H, s, C(CH3)3), 1.06 (3H, t, J = 7.0 Hz, CH2CH3), 3.17-
3.33 (2H, m, N-CH2), 3.76-3.79 (1H, m, C4’-H), 3.82 (1H, dd, J = 4.5, 11.5 Hz, C5’-H1), 
3.91 (1H, dd, J = 3.0, 11.5 Hz, C5’-H2),  4.07 (1H, app t, J = 6.5 Hz, C3’-H), 4.26 (1H, 
app t, J = 6.0 Hz, C2’-H), 5.26 (1H, d, J = 7.5 Hz, C5-H), 5.83 (1H, d, J = 6.0 Hz, C1’-
H), 7.38-7.49 (6H, m, Ar-H), 7.56-7.67 (5H, m, Ar-H, C4-H); C (100 MHz, DMSO-d6), 
14.9 (CH2CH3), 19.3 (Si-C(CH3)3), 27.1 (Si-C(CH3)3), 36.2 (N-CH2), 62.9 (C5’), 74.7 
(C3’), 76.0 (C2’), 82.9 (C4’), 85.8 (C1’), 104.4 (C5), 128.4 (Ar-C), 128.4 (Ar-C), 130.4 
(Ar-C), 130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.5 (Ar-C), 135.6 (Ar-
C), 139.4 (C4), 153.1 (C2), 170.0 (C6); max (thin film), 3303 (N-H), 1637 (C=O); m/z 
calculated for C27H35N3O5Si [M+H]
+, 510.2419, found 510.2432. 
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1.4.10 3-((2’R,3’S,4’S,5’R)-5’-((tert-
Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(propylamino)pyrimidin-6(1H)-one 30c 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100 mg, 
0.21 mmol, 1.0 eq) and propylamine (124 mg, 0.17 mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(propylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (80mg, 0.15 mmol, 
73%), mp = 197-198˚C. A drop of D2O was added to the analytical sample before the 1H 
NMR analysis. 
 H (400 MHz, DMSO-d6), 0.85 (3H, t, J = 7.5 Hz, CH2CH3), 1.01 (9H, s, C(CH3)3), 1.46-
1.55 (2H, m, CH2CH3), 3.09-3.25 (2H, m, N-CH2), 3.76-3.79 (1H, m, C4’-H), 3.83 (1H, 
dd, J = 4.5, 11.5 Hz, C5’-H1), 3.91 (1H, dd, J = 3.0, 11.5 Hz, C5’-H2), 4.06 (1H, app t, J 
= 6.5 Hz, C3’-H), 4.24 (1H, app t, J = 6.0 Hz, C2’-H), 5.25 (1H, d, J = 7.5 Hz, C5-H), 
5.87 (1H, d, J = 6.0 Hz, C1’-H), 7.41-7.50 (6H, m, Ar-H), 7.57 (1H,  J = 7.5 Hz, C4-H), 
7.61-7.65 (4H, m, Ar-H); C (100 MHz, DMSO-d6), 11.8 (CH2CH3), 19.3 (Si-C(CH3)3), 
22.2 (CH2CH3), 27.1 (Si-C(CH3)3), 43.1 (N-CH2), 62.9 (C5’), 74.5 (C3’), 76.0 (C2’), 82.8 
(C4’), 85.8 (C1’), 105.0 (C5), 128.4 (Ar-C), 128.4 (Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 
132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.5 (Ar-C), 135.6 (Ar-C), 139.3 (C4), 153.2 
(C2), 170.0 (C6); max (thin film), 3333 (N-H), 1636 (C=O); m/z calculated for 
C28H37N3O5Si [M+H]
+, 524.2575, found 524.2590. 
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1.4.11 3-((2’R,3’S,4’S,5’R)-5’-((tert-
Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(butylamino)pyrimidin-6(1H)-one 30d 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and butylamine (154 mg, 0.21 mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(butylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (75mg, 0.14 mmol, 
68%), mp = 199-200˚C. A drop of D2O was added to the analytical sample before the 1H 
NMR analysis. 
 H (400 MHz, DMSO-d6), 0.87 (3H, t, J = 7.0 Hz, CH2CH3), 1.00 (9H, s, C(CH3)3), 1.23-
1.32 (2H, m, CH2CH3), 1.43-1.51 (2H, m, CH2CH2CH3), 3.13-3.29 (2H, m, N-CH2), 3.76-
3.79 (1H, m, C4’-H), 3.82 (1H, dd, J = 4.5, 11.5 Hz, C5’-H1), 3.91 (1H, dd, J = 3.0, 11.5 
Hz, C5’-H2), 4.06 (1H, app t, J = 6.5 Hz, C3’-H), 4.24 (1H, app t, J = 6.0 Hz, C2’-H), 
5.25 (1H, d, J = 7.5 Hz, C5-H), 5.85 (1H, d, J = 6.0 Hz, C1’-H), 7.40-7.50 (6H, m, Ar-
H), 7.56-7.66 (5H, m, Ar-H, C4-H); C (100 MHz, DMSO-d6), 14.3(CH2CH3), 19.3 (Si-
C(CH3)3), 20.1 (CH2CH3), 27.1 (Si-C(CH3)3), 31.2 (CH2CH2CH3), 41.1 (N-CH2), 62.9 
(C5’), 74.7 (C3’), 76.0 (C2’), 82.9 (C4’), 85.9 (C1’), 105.0 (C5), 128.4 (Ar-C), 128.4 
(Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.5 (Ar-
C), 135.6 (Ar-C), 139.4 (C4), 153.2 (C2), 170.0 (C6); max (thin film), 3362 (N-H), 1636 
(C=O); m/z calculated for C29H39N3O5Si [M+H]
+, 538.2732, found 538.2735. 
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1.4.12 3-((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl) 
-3’,4’-dihydroxyoxolan-2’-yl)-2-(allylamino)pyrimidin-6(1H)-one 
30f 
 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and allylamine (120 mg, 0.17mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(allylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (72mg, 0.14 mmol, 
66%), mp 185-186˚C. A drop of D2O was added to the analytical sample before the 1H 
NMR analysis. 
 H (400 MHz, DMSO-d6), 1.01 (9H, s, C(CH3)3), 3.78-3.93 (5H, m, C4’-H, C5’-H1, C5’-H2, 
N-CH2), 4.08 (1H, app t, J = 6.5, C3’-H), 4.26 (1H, app t, J = 6.0 Hz, C2’-H), 5.06 (1H, 
d, J = 10.0 Hz, cis CH=CH2), 5.17 (1H, d, J = 17.0 Hz, trans CH=CH2), 5.25 (1H, d, J = 
7.5 Hz, C5-H), 5.82-5.89 (1H, m, CH2-CH=CH2), 5.91 (1H, d, J = 6.0 Hz, C1’-H), 7.41-
7.50 (6H, m, Ar-H), 7.58-7.67 (5H, m, Ar-H, C4-H); C (100 MHz, DMSO-d6), 19.3 (Si-
C(CH3)3), 27.1 (Si-C(CH3)3), 43.5 (N-CH2), 62.9 (C5’), 74.5 (C3’), 76.0 (C2’), 82.9 (C4’), 
85.9 (C1’), 105.2 (C5), 115.6 (CH=CH2), 128.4 (Ar-C), 128.4 (Ar-C), 130.4 (Ar-C), 
130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.5 (Ar-C), 135.6 (Ar-C), 135.8 
(CH=CH2), 139.3 (C4), 153.0 (C2), 169.9 (C6); max (thin film), 3336 (N-H), 1638 
(C=O); m/z calculated for C28H35N3O5Si [M+H]
+, 522.2419, found 522.2436. 
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1.4.13 3-((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl) 
-3’,4’-dihydroxyoxolan-2’-yl)-2-(iso-butylamino)pyrimidin-6(1H)-
one 30e 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and iso-butylamine (154mg, 0.21 mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl) -3’,4’-dihydroxyoxolan-2’-yl)-2-
(iso-butylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (72mg, 0.13 
mmol, 64%), mp = 197-198˚C. A drop of D2O was added to the analytical sample before 
the 1H NMR analysis. 
 H (400 MHz, DMSO-d6), 0.91 (6H, d, J = 6.5 Hz, CH(CH3)2), 1.06 (9H, s, C(CH3)3), 1.89-
1.99 (1H, m, CH(CH3)2), 3.01-3.16 (2H, m, N-CH2), 3.82-3.85 (1H, m, C4’-H), 3.88 (1H, 
dd, J = 4.5, 11.5 Hz, C5’-H1), 3.97 (1H, dd, J = 3.0, 11.5 Hz, C5’-H2), 4.12 (1H, app t, J 
= 6.5 Hz, C3’-H), 4.30 (1H, app t, J = 6.0 Hz, C2’-H), 5.29 (1H, d, J = 7.5 Hz, C5-H), 
5.94 (1H, d, J = 6.0 Hz, C1’-H), 7.46-7.56 (6H, m, Ar-H), 7.62 (1H, d, J = 7.5 Hz, C4-
H), 7.66-7.72 (4H, m, Ar-H); C (100 MHz, DMSO-d6), 19.3 (Si-C(CH3)3), 20.6 (CHCH3), 
20.7 (CHCH3), 27.1 (Si-C(CH3)3), 27.4 (CH(CH3)2), 48.8 (N-CH2), 62.9 (C5’), 74.7 (C3’), 
76.0 (C2’), 83.0 (C4’), 85.9 (C1’), 105.0 (C5), 128.3 (Ar-C), 128.4 (Ar-C), 130.4 (Ar-C), 
130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.5 (Ar-C), 135.6 (Ar-C), 139.3 
(C4), 153.3 (C2), 169.9 (C6); max (thin film), IR 3336 (N-H), 1638 (C=O); m/z 
calculated for C29H39N3O5Si [M+H]
+, 538.2732, found 538.2750. 
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1.4.14  3-((2’R,3’S,4’S,5’R)-5’-((tert-utyldiphenylsilyl)oxymethyl)  
-3’,4’-dihydroxyoxolan-2’-yl)-2-(benzylamino)pyrimidin-6(1H)-
one 30i 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and benzylamine (208 mg, 0.24 mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-utyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(benzylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (67mg, 0.12 
mmol, 56%), mp = 174-175˚C. A drop of D2O was added to the analytical sample before 
the 1H NMR analysis. 
 H (400 MHz, DMSO-d6), 1.02 (9H, s, C(CH3)3), 3.78-3.82 (1H, m, C4’-H), 3.85 (1H, dd, 
J = 4.0, 11.5 Hz, C5’-H1), 3.93 (1H, dd, J = 3.0, 11.5 Hz, C5’-H2),  4.10 (1H, app t, J = 
6.5 Hz, C3’-H), 4.29 (1H, app t, J = 6.0 Hz, C2’-H), 4.44-4.53 (2H, m, N-CH2), 5.25 (1H, 
d, J = 7.5 Hz, C5-H), 5.96 (1H, d, J = 6.0 Hz, C1’-H), 7.23-7.24 (1H, m, Ar-H), 7.30-
7.32 (3H, m, Ar-H), 7.42-7.50 (6H, m, Ar-H), 7.62-7.67 (5H, m, Ar-H, C4-H); C (100 
MHz, DMSO-d6), 19.3 (Si-C(CH3)3), 27.1 (Si-C(CH3)3), 44.2 (N-CH2), 62.9 (C5’), 74.5 
(C3’), 76.5 (C2’), 83.0 (C4’), 86.0 (C1’), 105.3 (C5), 127.0 (Ar-C), 127.5 (Ar-C), 128.4 
(Ar-C), 128.5 (Ar-C), 128.6 (Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 132.9 (Quat. Ar-C), 
133.2 (Quat Ar-C), 135.5 (Ar-C), 135.6 (Ar-C), 135.8 (Ar-C), 139.3 (C4), 140.0 (Quat. 
Ar-C), 153.2 (C2), 169.8 (C6); max (thin film), 3217 (N-H), 1640 (C=O); m/z calculated 
for C32H37N3O5Si [M+H]
+, 572.2575, found 572.2600. 
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1.4.15 3-((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl) 
-3’,4’-dihydroxyoxolan-2’-yl)-2-(cyclohexylamino)pyrimidin-
6(1H)-one 30j 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and cyclohexylamine (183 mg, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl) -3’,4’-dihydroxyoxolan-2’-yl)-2-
(cyclohexylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (60mg, 0.11 
mmol, 51%), mp = 178-179˚C. A drop of D2O was added to the analytical sample before 
the 1H NMR analysis. 
 H (400 MHz, DMSO-d6), 0.98 (9H, s, C(CH3)3), 1.14-1.28 (1H, m, aryl-H), 1.13-1.29 
(4H, m, aryl-H), 1.50-1.57 (1H, m, aryl-H), 1.61-1.68 (2H, m, aryl-H), 1.73-1.81 (2H, 
m, aryl-H), 3.72-3.78 (2H, m, C4’-H, NH-CH), 3.81 (1H, dd, J = 4.5, 11.5 Hz, C5’-H1), 
3.91 (1H, dd, J = 3.0, 11.5 Hz, C5’-H2), 4.08 (1H, app t, J = 6.5, C3’-H), 4.28 (1H, app 
t, J = 6.0, C2’-H), 5.26 (1H, d, J=7.5 Hz, C5-H), 5.85 (1H, d, J = 6.0, C1’-H), 7.36-7.48 
(6H, m, Ar-H), 7.57-7.61 (4H, m, Ar-H), 7.65 (1H, d, J = 7.5 Hz, C4-H); C (100 MHz, 
DMSO-d6), 15.6 (CH2), 19.3 (Si-C(CH3)3), 25.5 (CH2), 25.8 (CH2), 27.1 (Si-C(CH3)3), 
32.5 (CH2), 32.7 (CH2), 50.2 (N-CH), 63.0 (C5’), 74.7 (C3’), 76.0 (C2’), 82.9 (C4’), 85.7 
(C1’), 105.0 (C5), 128.4 (Ar-C), 128.4 (Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 132.9 (Quat. 
Ar-C), 133.2 (Quat Ar-C), 135.4 (Ar-C), 135.6 (Ar-C), 139.7 (C4), 152.5 (C2), 169.9 
(C6); max (thin film), 3249 (N-H), 1636 (C=O); m/z calculated for C31H41N3O5Si [M+H]+, 
564.2888, found 564.2912. 
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1.4.16  3-((2’R,3’S,4’S,5’R)-5’-((tert-
Butyldiphenylsilyl)oxymethyl) -3’,4’-dihydroxyoxolan-2’-yl)-2-
(pentylamino)pyrimidin-6(1H)-one 30g 
 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and amylamine (183 mg, 0.24 mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl) -3’,4’-dihydroxyoxolan-2’-yl)-2-
(pentylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (71mg, 0.13 mmol, 
61%), mp = 185-186˚C. A drop of D2O was added to the analytical sample before the 1H 
NMR analysis. 
 H (400 MHz, DMSO-d6), 0.86 (3H, t, J = 7.0 Hz, CH3), 1.01 (9H, s, C(CH3)3), 1.22-1.33 
(4H, m, alkyl-H), 1.46-1.54 (2H, m, NCH2CH2), 3.12-3.29 (2H, m, N-CH2), 3.76-3.79 
(1H, m, C4’-H), 3.82 (1H, dd, J = 4.5, 11.5 Hz, C5’-H1), 3.92(1H, dd, J = 3.0, 11.5 Hz, 
C5’-H2),  4.06 (1H, app t, J = 6.5, C3’-H), 4.26 (1H, app t, J = 6.0, C2’-H), 5.24 (1H, d, 
J = 7.5 Hz, C5-H), 5.87 (1H, d, J = 6.0, C1’-H), 7.40-7.50 (6H, m, Ar-H), 7.56 (1H, d, J 
= 7.5 Hz, C4-H), 7.61-7.67 (4H, m, Ar-H); C (100 MHz, DMSO-d6), 14.4 (CH2CH3), 19.3 
(Si-C(CH)3), 22.5 (CH3CH2), 27.1 (Si-C(CH3)3), 28.7 (CH2), 29.1 (CH2), 41.4 (N-CH2), 
62.9 (C5’), 74.7 (C3’), 76.0 (C2’), 82.9 (C4’), 85.8 (C1’), 104.9 (C5), 128.4 (Ar-C), 
128.4 (Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.4 
(Ar-C), 135.6 (Ar-C), 139.4 (C4), 153.1 (C2), 170.0 (C6); max (thin film), 3363 (N-H), 
1634 (C=O); m/z calculated for C30H41N3O5Si [M+H]
+, 552.2888, found 552.2911. 
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1.4.17  3-((2’R,3’S,4’S,5’R)-5’-((tert-
Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(hexylamino)pyrimidin-6(1H)-one 30h 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and hexylamine (212mg, 0.28 mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(hexylamino)pyrimidin-6(1H)-one was obtained as a colourless solid (62mg, 0.11 mmol, 
52%), mp = 181-182˚C. A drop of D2O was added to the analytical sample before the 1H 
NMR analysis. 
 H (400 MHz, DMSO-d6), 0.81 (3H, t, J = 7.0 Hz, CH3), 0.98 (9H, s, C(CH3)3), 1.19-1.26 
(6H, m, alkyl-H), 1.42-1.50 (2H, m, NCH2CH2), 3.12-3.29 (2H, m, N-CH2), 3.75-3.79 
(1H, m, C4’-H), 3.82 (1H, dd, J = 4.5, 11.5 Hz, C5’-H1), 3.91-3.93 (1H, m, C5’-H2), 4.07 
(1H, app t, J = 6.5, C3’-H), 4.26 (1H, app t, J = 6.0, C2’-H), 5.26 (1H, d, J=7.5 Hz, C5-
H), 5.84 (1H, d, J = 6.0, C1’-H), 7.38-7.48 (6H, m, Ar-H), 7.58-7.64 (4H, m, Ar-H, C4-
H); C (100 MHz, DMSO-d6), 14.4 (CH2CH3), 19.3 (Si-C(CH3)3), 22.6 (CH3CH2), 26.6 
(CH2), 27.1 (Si-C(CH3)3), 29.0 (CH2), 31.6 (CH2), 41.4 (N-CH2), 62.9 (C5’), 74.7 (C3’), 
76.0 (C2’), 82.9 (C4’), 85.3 (C1’), 104.9 (C5), 128.4 (Ar-C), 128.4 (Ar-C), 130.4 (Ar-C), 
130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.4 (Ar-C), 135.5 (Ar-C), 139.4 
(C4), 153.1 (C2), 170.0 (C6); max (thin film), 3364 (N-H), 1635 (C=O); m/z calculated 
for C31H43N3O5Si [M+H]
+, 566.3045, found 566.3052. 
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1.4.18 3-((2’R,3’S,4’S,5’R)-5’-((tert-
Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(iso-pentylamino)pyrimidin-6(1H)-one  30k 
 
 
 
 
Following general amination procedure from 5’-O-TBDPS-2,2’-anhydrouridine (100mg, 
0.21 mmol, 1.0 eq) and iso-pentylamine (183 mg, 0.24 mL, 2.1 mmol, 10.0 eq) 3-
((2’R,3’S,4’S,5’R)-5’-((tert-Butyldiphenylsilyl)oxymethyl)-3’,4’-dihydroxyoxolan-2’-yl)-2-
(iso-pentylamino)pyrimidin-6(1H)-one was as a colourless solid (67mg, 0.12 mmol, 
58%), mp = 182-183˚C. A drop of D2O was added to the analytical sample before the 1H 
NMR analysis. 
 H (400 MHz, DMSO-d6), 0.89 (6H, d, J = 6.5 Hz, CH2(CH3)2), 1.02 (9H, s, C(CH3)3), 
1.38-1.43 (2H, m, CH2CH(CH3)2), 1.54-1.64 (1H, m, CH(CH3)2), 3.15-3.32 (2H, m, N-
CH2), 3.76-3.79 (1H, m, C4’-H), 3.82 (1H, dd, J = 4.5, 11.5 Hz, C5’-H1), 3.91 (1H, dd, J 
= 3.0, 11.5 Hz, C5’-H2), 4.06 (1H, app t, J = 6.5, C3’-H), 4.23 (1H, app t, J = 6.0, C2’-
H), 5.24 (1H, d, J = 7.5 Hz, C5-H), 5.86 (1H, d, J = 6.0, C1’-H), 7.42-7.48 (7H, m, Ar-
H), 7.61-7.66 (5H, m, Ar-H, C4-H); C (100 MHz, DMSO-d6), 19.3 (Si-C(CH3)3), 23.0 
(CHCH3), 25.8 (CH(CH3)2), 27.1 (Si-C(CH)3), 38.0 (NHCH2CH2), 39.7 (N-CH2), 62.9 
(C5’), 74.7 (C3’), 76.0 (C2’), 82.9 (C4’), 85.8 (C1’), 105.0 (C5), 128.4 (Ar-C), 128.4 
(Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 132.9 (Quat. Ar-C), 133.2 (Quat Ar-C), 135.5 (Ar-
C), 135.6 (Ar-C), 139.4 (C4), 153.1 (C2), 169.9 (C6); max (thin film), 3330 (N-H), 1637 
(C=O); m/z calculated for C30H41N3O5Si [M+H]
+, 552.2888, found 552.2906 
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2. Functionalised Amino Acids via the Belluš-
Claisen Rearrangement  
 
2.1 Introduction  
 
2.1.1 Amino Acids and Peptides  
 
Amino acids are organic molecules that have both an amine (-NH2) and a carboxyl        
(-COOH) functional group.64 Amino acids usually refers to the amino-alkanoic acids, 
N3H
+-(CR1R2)n-CO2- where n = 1 for amino acids, n = 2 for  amino acids and so on. 
Figure 7 depicts the structure of an amino acid where R is a side chain. The differing 
side groups, R, determine the properties of the amino acids. 
 
 
Figure 7: Amino Acid Structure65 
 
Hundreds of amino acids have been discovered which occur in living organisms and the 
majority are -amino acids.66 They can be present as a single amino acid or as 
components of peptides, proteins and other amides.64 A peptide consists of a chain of 
fifty amino acids or less which are joined by peptide bonds. A polypeptide consists of 
chains of more than fifty amino acids and proteins are formed of several polypeptides.65 
Nineteen amino acids and one imino acid, proline,67 are used by cells for protein 
synthesis. These are called proteogenic, or primary, amino acids and are found within 
proteins that are coded for the standard genetic code.65 With the exception of glycine, all 
proteogenic amino acids have an asymmetric centre and thus can have two 
enantiomers.68 Enantiomers are non-superimposable mirror images (Figure 8).69 Proteins 
and the majority of naturally occurring peptides contain the L-amino acids.  
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Figure 8: Enantiomers of Proline 
 
Amino acids have shown a wide range of biological activities and are used for a range of 
treatments. For example, tyrosine is a precursor of the neurotransmitters 
norepinephrine, epinephrine and dopamine which are used for mood regulation and 
therefore tyrosine supplements have been used for stress reduction.70,71  Cysteine is 
needed for the skin facilitating the production of collagen and it also helps in detoxifying 
harmful toxins. Cysteine supplements have also been tried in the treatment of  
arthritis.72,73 L-Glutamine is used to maintain the lining of the gut as well as other 
essential functions such as the immune system. L-Glutamine supplements have been 
used to treat Irritable Bowel Syndrome.74 Further, in addition to nutritional supplements, 
amino acids are used in the synthesis of other products such as cosmetics and 
surfactants.75,76 
 
Most proteogenic acids are readily available, and can be bought in gram quantities for a 
modest cost especially compared to other enantiomerically pure compounds. However, in 
addition to the primary amino acids, there are hundreds of non-proteogenic amino acids 
that are not used in protein synthesis.64 These have become important as tools for 
modern drug discovery research, particularly when incorporated into peptides.77,78 It is 
possible to acquire non-proteogenic amino acids from nature, but this involves 
harvesting from natural sources that can be time-consuming and expensive. Therefore it 
is preferable to synthesize these products in the laboratory where possible.    
 
This study investigates the application of Belluš-Claisen rearrangement as a method of 
producing non-protegenic amino acids and dipeptides in a one-pot reaction.  
 
2.1.2 The Claisen Rearrangement  
 
The Claisen rearrangement has seen wide use in synthetic organic chemistry because of 
the stereoselective nature of the bond formation, and the potential to obtain useful 
polyfunctionalised products.79,80 The reaction’s usefulness is reflected in the extensive 
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library of research that has been published and modern variants have secured the 
continued reputation of this highly useful synthetic tool.79  
 
The process discovered in 1912 by Ludwig Claisen, was the first recorded example of a 
[3,3]-sigmatropic rearrangement.81,80  A sigmatropic rearrangement occurs in an  
intramolecular process whereby a -bond is created between atoms that were not linked 
and a previous bond is broken i.e. the -bond migrates (Figure 9 and Figure 10). 
 
 
 
Figure 9: A [3,3] sigmatropic rearrangement82 
 
Two numbers set in the brackets [i,j] are used to specify the order of a sigmatropic 
rearrangement. These numbers can be ascertained by counting the atoms from the 
original position that the bond has moved from. Each of the original termini is given 
the number 1. Thus in Figure 9, each terminus of the -bond has migrated from C-1 to 
C-3, so the order is [3,3].  
 
Figure 10: A [1,5] sigmatropic rearrangement82 
 
In Figure 10, the carbon terminus has moved from C-1 to C-5, but the hydrogen 
terminus has not moved at all, so the order is [1,5].82  
 
The [3,3]-sigmatropic rearrangement is a reliable and proven method for the 
stereoselective construction of carbon–carbon or carbon–heteroatom bonds.83 The 
Claisen rearrangement is a [3,3]-sigmatropic rearrangement of an allyl vinyl ether 38 to 
give the corresponding ,-unsaturated carbonyl compound 39 (Scheme 11).80 Formerly, 
the Claisen reaction specifically refers to an allylic ether, with the aza-Claisen and thio-
Claisen referring to rearrangements of allylic amines and allylic sulphides respectively. 
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Scheme 11: The Claisen Rearrangement80 
  
Claisen substrates proceed through highly ordered six-membered transition states 
allowing control over the stereochemistry depending on the precursors.                         
(Scheme 12).84 
 
 
Scheme 12: Highly ordered six-membered transition state84  
 
Subsequent research by other groups found that the conditions reported by Claisen on 
aromatic substrates could be successfully applied to aliphatic skeletons. For example, 
ethyl -cinnamyloxycrotonate 43 undergoes a [3,3] rearrangement to give keto ester 
44 under heating in the presence of ammonium chloride (Scheme 13).80,85 
 
 
Scheme 13: Rearrangement of ethyl -cinnamyloxycrotonate  
 
Claisen rearrangements of allyl vinyl ethers need high temperatures, about 200 oC.86 
Such harsh conditions can lead to decomposition of the final product.  Further, synthesis 
of the vinyl ether moiety starting material is a challenging process. Many variants have 
been reported where attempts have been made to enable a synthetically useful process 
using milder experimental conditions, faster reaction times or generating the 
intermediate in situ to bypass the need to synthesize the starting material 
separately.80,85  The methods used included the use of different substituents, different 
methods to access a suitable intermediate to undergo [3,3] sigmatropic rearrangement 
and variations in the carbon skeleton of the substrate as well as the catalyst, if any.80,87 
Some examples are discussed below. 
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2.1.3 Claisen Variants  
 
2.1.3.1 The Eschenmoser-Claisen Rearrangement.  
 
The Eschenmoser-Claisen rearrangement is considered to be one of the more useful 
pericyclic reactions.88 Building on the investigation of amide acetals by Meerwein et al.,89 
Eschenmoser reported that heating allylic alcohols 45 with dimethylacetamide dimethyl 
acetal 46 gave -unsaturated amide 48 (Scheme 14).84,90 Following alcohol exchange 
and elimination of methanol intermediate ketene N,O-acetal 47 is formed in situ. This 
undergoes [3,3] sigmatropic rearrangement to give resulting product. The electron 
donating amino substituent in the intermediate drastically increases the reaction rate of 
the pericyclic step.84 
 
 
Scheme 14: The Eschenmoser–Claisen Rearrangement 
 
Compared to the Johnson and Ireland variants mentioned below, the Eschenmoser 
version often provides better yields with superior stereo-selectivity. The reaction also 
has the advantage of employing neutral conditions in the formation of the N,O-ketene 
intermediate which allows sensitive substrates to be used in the reaction, provided that 
they can withstand the high temperatures that are frequently required. The 
Eschenmoser–Claisen rearrangement has proven to have extensive scope and has been  
used in the synthesis of complex molecules,91 steroids,92 drugs and natural products.93,94,     
Hart and Chen (1993) employed the Eschenmoser-Claisen rearrangement as one of the 
key steps in the first total synthesis of stenine 5195. The primary alcohol had to be TBS 
protected to prevent competitive activation and cyclization. After protection, silyl ether 
49 was refluxed with dimethylacetamide dimethyl acetal 46 in xylenes for 4 hours to 
give the desired amide 50 in excellent 93% yield (Scheme 15). 
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Scheme 15: The Eschenmoser–Claisen Rearrangement used in total synthesis of stenine 5195  
 
2.1.3.2 The Johnson Rearrangement.  
 
The Johnson-Claisen rearrangement is closely related to the Eschenmoser 
rearrangement, proceeding through a ketene acetal. Here, an allylic alcohol 53 is heated 
with ethyl orthoacetate 52 and acid to give mixed ortho ester 54. The ortho ester 54 
then loses ethanol to generate the ketene acetal 55 which proceeds to undergo 
rearrangement to give to ,-unsaturated ester 56 (Scheme 16).96 The traditional Claisen 
rearrangement, namely the allyl vinly ether rearrangement, is typically a two-step 
process but in the Johnson-Claisen rearrangement the ketene acetal formation and the 
rearrangement are completed in one step.90  
 
 
Scheme 16: The Johnson–Claisen Rearrangement 
 
The Johnson-Claisen rearrangement has been used in the synthesis of steroids,97 
prostaglandins,98 antitumour compounds,99 and alkaloids.100,101 Danishefsky et al. (2002) 
used the Johnson-Claisen rearrangement to synthesize a key intermediate in their total 
synthesis of gelsemine (Figure 11).  
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Figure 11: Gelsemine 
 
A Horner-Wadsworth-Emmons condensation, followed by reduction of the ketone of the 
allylic alcohol, gave a mixture of stereiosmers 58. The Johnson-Claisen rearrangement 
was cleverly employed whereby treatment with triethylorthoacetate and a catalytic 
amount of propionic acid gave the identical ,-unsaturated ester 60 with both the -
vinyl and -caroxymethyl functionalities at the correct positions for the following 
synthetic steps (Scheme 17)102. 
 
 
 
Scheme 17: Synthesis of ,-unsaturated ester 60 102  
 
2.1.3.3 The Ireland-Claisen Rearrangement 
 
The Ireland-Claisen rearrangement represented a significant development of the Claisen 
rearrangement because, compared to other rearrangements, this reaction proceeded 
under milder conditions with temperatures under 100˚C.103,104The inspiration for this 
work was a study by Rathke and Lindert in 1971, who demonstrated that it was possible 
to generate ester enolates under mild conditions.105,106 Ireland and Mueller reported the 
rearrangement of allyl trimethylsilyl ketene acetal 63, prepared by formation of allylic 
ester enolate 62 from ester 61 followed by reaction with trimethylsilyl chloride. The 
subsequent rearrangement followed by hydrolysis gave the ,-unsaturated carboxylic 
acid 64 (Scheme 18).  
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Scheme 18: Ireland-Claisen Rearrangement103 
 
The Ireland-Claisen reaction has a number of advantages including the ease of synthesis 
of the ester enolate, the ability to control E/Z selectivity in the product, a frequently high 
degree of transference of chirality from the starting material to the newly formed 
stereocenters in product 64 and a high degree of alkene stereocontrol. It has thus been 
widely developed in organic syntheses and has been used in various applications 
including the synthesis of polyether antibiotics107, natural products108 and the 
preparation of polyfunctionalised structures.80,109  
 
Corey et al. (1999) used the Ireland-Claisen rearrangement as part of the first total 
synthesis of aspidophytine 67 more than a quarter of a century after the elucidation of 
its structure.110 A key intermediate, isopropyl ester 66, was derived by treating allylic 
acetate 65 with LDA and TBSCl to give a chiral carboxylic acid. Esterification with EDCl 
as the coupling reagent provided the desired ester in 57% overall yield (Scheme 19). 
 
Scheme 19: Ireland-Claisen Rearrangement used in total synthesis of aspidophytine 67 110  
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2.1.3.4 The Reformatsky-Claisen Rearrangement.  
 
The [3,3] sigmatropic rearrangement of zinc enolates, termed the Reformatsky-Claisen 
rearrangement, was reported in 1973.111 Baldwin’s study showed that zinc enolates, 
generated by the Reformatsky reaction of αhaloesters 68 with zinc dust, at 80 to 140 
˚C, led to the corresponding Ȗ,δ-unsaturated zinc carboxylates 70 via enolate 69 
(Scheme 20).  This work was significant in that it proceeded under neutral conditions. 
Yields varied widely depending upon substitution and the solvent used. For example, 
when R1=R2=Me and R3=R4=H, using the solvent was benzene and a temperature of 
80˚C, a stoichiometric yield was reported. The yield drastically changed to less than 
15% when R1=R2=R3=R4=H, xylene was the solvent and the temperature was 140 ˚C.111 
 
 
 
 
Scheme 20: Reformatsky-Claisen Rearrangement111 
 
The Reformatsky-Claisen rearrangement will also proceed when a silylating agent is 
used, where the most probable intermediate is a silyl ketene acetal. The rearrangement 
most often reported in the literature involve heating a substrate with zinc dust and a 
silylating reagent in a polar aprotic solvent.84,112,113  
 
An example of its synthetic application was the rearrangement of fluorinated substrates.  
Fluorinated ketones have been found to be effective enzyme inhibitors.114 With this 
discovery the ability to synthesize molecules with fluorine substituents adjacent to a 
carbonyl group became a major research target. This was one of the earliest applications 
of the Reformatsky-Claisen rearrangement, for example the conversion of allyl 
chlorodifluoroacetate 71 to difluoroacid 72 (Scheme 21).115  
 
 
Scheme 21: Synthesis of difluoroacid 72115 
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2.1.4 The Belluš-Claisen Rearrangement  
 
In 1978, Belluš and Malherbe discovered a new ketene-Claisen reaction during an 
attempt to prepare the 2-chlorocyclobutanone derivative 77 (Scheme 22).116,117 
 
 
Scheme 22: First observation of the Belluš-Claisen Rearrangement116 
 
Chloro(trichloroethyl)ketene 74 was prepared from acyl chloride 73 via zinc copper 
couple catalysed dehalogenation. When ketene 74 was then reacted with allylic ether 75 
at ambient room temperature a mixture of products was obtained, comprised of the 
desired [2+2] cycloaddition product 77 and the -unsaturated ester 79. On analysis it 
was found that this byproduct was the result of an alternate reaction pathway, where the 
nucleophilic oxygen atom of the allylic ether 75 can compete successfully with the 
double bond in 75 for the electrophilic ketene. This meant that, as well as expected 
intermediate 76, zwitterionic enolate intermediate 78 was also formed. This is perfectly 
set up to undergo [3,3]-sigmatropic rearrangements to give ,- unsaturated ester 79. 
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The original Claisen reaction required high temperatures and since the 1970s, cation-
accelerated  and anion-accelerated rearrangements have been utilised to reduce the 
temperature of the reaction, speed up the rate and to enable the synthesis of a wider 
range of molecules that might otherwise decompose at higher temperatures.118,119 For 
example, the Ireland Claisen rearrangement is an anion accelerated process.103,120 The 
Belluš-Claisen rearrangement was the first reported rearrangement that had a 
zwitterionic intermediate.116 The effect on the reaction is extraordinary and is due to 
charge neutralisation providing a significant driving force. Whereas a typical Claisen 
rearrangement needs temperatures in excess of 150˚C to proceed, the Belluš-Claisen 
rearrangement will occur readily at room temperature.  
 
 
Figure 12: Dipole Accelerated Claisen Rearrangements 
 
It was reported that the new reaction could tolerate a broad range of cyclic and acyclic 
ethers and sulfides 83 to give the corresponding of ,-unsaturated ester and thioester 
85 (Scheme 23).116   
 
  
Scheme 23: General scheme for first reported Belluš-Claisen Rearrangement116  
 
This research inspired work undertaken by the MacMillan group, who conducted a 
thorough investigation into a novel acyl-Claisen reaction based on the Belluš-Claisen 
variant. The range of ketenes that could be used were highly limited and it was reported 
that only highly electrophilic ketenes such as dichloroketene and 
chloro(trichloroethyl)ketene were found to work satisfactorily.117 Detailed inspection of 
these reports by the MacMillan group discovered an alternate explanation. They reported 
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that the only productive reactions were those where the ketenes were generated by in 
situ zinc dehalogenation.121 The MacMillan group determined that the zinc chloride 
(ZnCl2) produced during the reaction was not just an unwanted by-product, but in fact, 
was an essential part of the reaction122. Using Lewis acids to activate ketenes is not an 
unknown process123 and it seemed likely that a Lewis acid was activating the ketene 
towards nucleophilic attack. 
 
This theory was supported by attempts to use chlorocyanoketene 87, a highly electron 
deficient ketene, in the Belluš-Claisen reaction. The chlorocyanoketene was generated by 
thermolysis (Scheme 24) and the reaction was therefore performed without any Lewis 
acidic metal salt to act as a catalyst. Less than 5% of the product arising from a Claisen 
rearrangement could be isolated, even when elevated temperatures were used.124  
 
 Scheme 24: Generation of chlorocyanoketene124  
 
 
The MacMillan group determined that Lewis acid activated ketene 90 would be 
susceptible to the addition of a tertiary allylic amine 91 (Scheme 25).124  
 
 
 
Scheme 25: New Lewis Acid-Catalysed Claisen Rearrangement122 
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2.1.4.1 Enantioselective Claisen Rearrangements.  
   
Several studies have reported the fact that, in the presence of Lewis acids, Claisen 
rearrangements are accelerated.125,126 This led to the study of the effects of chiral Lewis 
acids relating to the enantioselectivity of the reaction in an attempt to determine ligands 
which accelerate the reaction and achieve optimum chirality transfer.80 
 
In 2002, Hiersemann and Abraham reported the first successful enantioselective catalytic 
Claisen Rearrangement (Scheme 26).  Chiral bis(oxazoline)copper(II) 96 was used to 
catalyse the rearrangement of 2-alkoxycarbonyl-substituted allyl vinyl ethers 95 in a 
bidentate manner. Very high yields were reported (94% to 100%).127 
 
 
Scheme 26: The catalytic enantioselective Claisen Rearrangement of 2-alkoxycarbonyl-
substituted allyl vinyl ethers127 
 
The scope of this reaction is limited because of the necessity for an ester group at the 2-
position to act as a chelating group and the difficulties in the synthesis of allyl vinyl ether 
moieties.127 The MacMillan group sought to develop an enantioselective catalytic Claisen 
rearrangement which had general synthetic ability. 
 
2.1.4.2 Enantioselective Acyl-Claisen Rearrangement.  
 
The MacMillan group also looked into developing an enantioselective catalytic Claisen 
rearrangement as part of their work on the acyl-Claisen rearrangement. This led to the 
development of several chiral Lewis acids of which 98 was found to be the most effective 
(Figure 13). 
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Figure 13: Chiral Lewis acid complex 98128 
 
 
Using this Lewis acid catalyst the first example of an enantioselective acyl-Claisen 
reaction was reported128 However, when published in 2001 this reaction was not 
catalytic. It required a large excess of the Lewis acid to give good enantiomeric 
selectivity (Scheme 27 and Table 5). The MacMillan group theorized that this was due to 
a competing non-metal mediated rearrangement pathway.124  
 
 
 
Scheme 27: Catalysed Acyl-Claisen Rearrangement128 
 
 
 
 
Table 5: Effect of chiral Lewis acid loading 
 
Entry Mol % 98 Yield (%) ee (%) 
1 50 81 42 
2 100 63 81 
3 200 80 91 
 
 
When the Belluš-Claisen reaction is performed using allylic amines (Scheme 28)116 the 
reaction proceeds via zwitterion 104, formed from the allylic amine 102 upon reaction 
with a ketene 103. The ketene used can be an isolated starting material or generated in 
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situ, such as from dehydrohalogenation of an acyl chloride. When using an acyl chloride 
it is possible that the allylic amine may react with the acyl chloride 105 to form an acyl 
ammonium salt 106. This is physically incapable of undergoing the desired [3,3] 
rearrangement. Only after dehydrohalogenation of the salt can the rearrangement to 
give the desired amide 107 take place. 
 
 
 
Scheme 28: Mechanism of Belluš-Claisen Rearrangement116 
 
The MacMillan group found that various Lewis acids were able to catalyze the reaction of 
substituted ketenes with a range of allylic tertiary amine substrates. However their initial 
method of ketene generation was not ideal. Bromoacetyl bromide was treated with zinc 
in THF and the resulting ketene was co-distilled with the THF solution at reduced 
pressure into a liquid nitrogen cooled Schlenk flask. This procedure had two major 
drawbacks: 
1) It was necessary to co-distil the ketenes with ethereal solvents and so the 
molecular weight of the ketenes had to be low. 
2) There was a degree of inaccuracy because it was extremely difficult to work out 
the concentration of the ketene solution produced and thus it was normally used 
in considerable excess. 
 
After some research, an alternate method for ketene generation was chosen for the 
remainder of their investigation. Base-promoted dehydrohalogenation of acid chlorides 
had been used for over a century and was first demonstrated in 1911 by Staudinger.129 
The method is robust and is capable of generating a broad range of mono and di 
substituted ketenes. Furthermore, there was evidence of trapping the generated ketenes 
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in situ with differing reaction mixtures, for example with enol silanes, alkenes, carbonyl 
compounds and imines.130 Most importantly from the view of the MacMillan group, this 
reaction generated ketenes without generating Lewis acid metal byproducts.124  
 
We proposed to extrapolate the Belluš-Claisen rearrangement to prepare functionalised 
amino acids by C-allylation. As proof of concept the reaction was to be first attempted by 
reacting N-phthaloylglycyl chloride 108 with a N,N-dimethyl amine 109. (Scheme 29). 
This was very similar to the MacMillan work so we expected this to be successful. 
  
Scheme 29: Proposed scheme for synthesis of 2-Phthaloyl-N,N-dimethylpent-4-enamide  
 
 
If the reaction could be made to work satisfactorily it would then be repeated with 
suitable allylated amino acid derivatives 111 to synthesize non-proteinogenic dipeptides 
112 (Scheme 30). 
  
Scheme 30: Proposed scheme for synthesis of non-proteogenic dipeptides  
 
 
If this general reaction scheme proved viable, it was hoped that the rearrangement could 
then be applied to more peptides such as 113 (Scheme 31). This would give a process 
that allows addition of an amino acid to a peptide chain as well as creation of a new 
stereocentre to give -allylated peptides like 114 using a single rearrangement reaction.  
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Scheme 31: Proposed scheme for [3,3] Belluš Claisen Rearrangement performed on generic 
peptide 
 
2.2 Results and Discussion 
 
A Belluš-Claisen rearrangement was carried out using N,N-dimethyl allyl amine 109 
(Scheme 33). This reagent was chosen because structurally it was the least complex 
tertiary amine that could be used in the [3,3] sigmatropic rearrangement. N-phthaloyl 
protected glycyl chloride 108 was chosen for the ketene precursor, which was 
synthesized from commercially available N-phthaloyl glycine 115 following a procedure 
by Balenovic et al.(Scheme 32)131 
 
  
Scheme 32: Synthesis of N-phthaloylglycyl chloride 3131 
 
The MacMillan group had already reported a successful rearrangement using N-
phthaloylglycyl chloride as the ketene precursor. However, the amine used in their 
example was an allyl morpholine derivative that had a number of advantages over the 
dimethylallyl amine that we wished to use. Firstly, the electron-withdrawing ability of the 
morpholine oxygen can increase the speed of the sigmatropic rearrangement by 
destabilizing the cationic charge on the nitrogen of the zwitterionic intermediate. 
Secondly, the separation of the product from the metal centre can be improved. This is 
due to the relatively weaker electron donating capability of the morpholine nitrogen 
which will make the amide carbonyl produced in the reaction less Lewis basic. In theory, 
this improves the rate of the catalyst turnover and also increases the speed of the 
reaction.124,128               
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Reaction of N-phthaloylglycyl chloride 108 with diisopropylethylamine gives ketene 116 
(Scheme 33). This is followed by nucleophilic attack on the ketene by dimethylallylamine 
109 to give zwitterionic intermediate 117. This underwent [3,3] sigmatropic 
rearrangement to give amide 110. Titanium tetrachloride was used as the Lewis acid in 
this reaction.  
 
   
Scheme 33: Synthesis of 2-phthaloyl-N,N-dimethylpent-4-enamide 
 
1H NMR analysis showed the appearance of the expected product in the reaction 
mixture. The creation of a new asymmetric centre was supported by the appearance in 
the 1H NMR of a splitting pattern at 2.78-3.20 characteristic of diastereotopic protons  
to an asymmetric center (Figure 14). 
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Figure 14: 1H NMR of 2-phthaloyl-N,N-dimethylpent-4-enamide 108 showing AB splitting pattern 
at 2.76-3.21 ppm 
 
 
A similar splitting pattern is reported for N-phthaloylallylglycine 118 at 2.90-3.14 (Figure 
15).132 Following purification by column chromatography an overall yield of 6% was 
obtained.  
 
 
Figure 15: N-phthaloylallylglycine132 
 
Titanium tetrachloride is a strong Lewis acid that has been used to considerably improve 
the electrophilicity of substrates. It has been successfully utilised in Diels-Alder  
reactions but it can create side reactions resulting in product decomposition.133,134,135 
Likewise, while it has successfully been used in Belluš-Claisen reactions with a selection 
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of simple allylic tertiary amines, when used with more complex allylic amines often 
results in product decomposition or recovery of starting material.79 Due to this alternate 
Lewis acids were considered. 
 
TMS triflate 119 (Figure 16) is a milder Lewis acid which has been used successfully in 
Belluš-Claisen rearrangements.79 Repeating the reaction, this time with a stoichiometric 
quantity of silyl triflate, did give a significant improvement with a final yield of 29%. 
During these attempts to improve yield it was also noted that the purity of N-
phthaloylglycyl chloride 108 had a significant effect on the final yield. Either freshly 
prepared or freshly recrystallized material was necessary to get full conversion of the 
reaction to the desired starting material. 
 
 
Figure 16: TMS triflate 
 
The next attempt to increase the yield was the use of ytterbium triflate as the Lewis acid 
catalyst. Ytterbium triflate catalyzed Claisen rearrangements in good yields have been 
reported.122,136,137 The reaction was repeated using ytterbium triflate (Scheme 34).  
 
Scheme 34: Alternate Lewis acid catalyst 
 
Ytterbium triflate was bought as the hydrate and had to be dried before use. Unless 
sufficiently dried before use, ytterbium triflate can give poor yields when being used as a 
Lewis acid.138 Initially the reaction was attempted using ytterbium triflate hydrate that 
had been pre-dried under 0.7 mm pressure using a high vacuum oil pump for three 
hours. However, this failed to give any of the desired product. 
 
After this significantly harsher conditions were used to dry the catalyst. The reaction was 
repeated using ytterbium triflate that had been left to dry for 16 hours under 0.7 mm 
vacuum at 140 ˚C. This gave a quantitative crude yield, with 1H NMR analysis showing 
the majority to be product. On being left to stand, the crude product solidified. Re-
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crystallisation from an IPA/iPr2O mixture gave pure 2-phthaloyl-N,N-dimethylpent-4-
enamide, in 57% yield. 
 
An alternate protecting group for the ketene precursor was also investigated. N-Tosyl 
glycine 121 was synthesized and converted to acid chloride 122 using literature 
methods.139 However, attempts to perform the Belluš-Claisen using acid chloride 122 
proved unsuccessful. All attempts to perform the rearrangement using acid chloride 122 
returned only starting materials and N-tosyl glycine 121.   
 
 
Scheme 35: N-Tosyl glycyl chloride synthesis 
 
2.2.1 Application to Amino Acids  
 
The next step was to apply this chemistry to allylated amino acids anaolgues and to 
investigate whether a chiral molecule would affect the selectivity of the generating of the 
new asymmetric centre in the rearranged product. The first experiment was performed 
on the simplest available chiral amino acid, alanine. The methyl ester hydrochloride salt 
was refluxed in acetonitrile with allyl bromide and sodium hydrogen carbonate to give 
the desired allylated analogue. Purification by flash column chromatography gave N,N-
diallyl alanine methyl ester 123 in 72% yield. The rearrangement reaction was 
attempted using the previously tried conditions: diisopropylethylamine, N-phthalylglycyl 
chloride and ytterbium triflate as the Lewis acid catalyst (Scheme 36). 
 
 
Scheme 36: Belluš-Claisen Rearrangement of N,N-diallyl alanine methyl ester 
 
 
On the first attempted rearrangement, a mixture of starting material and rearranged 
products 124 and 125 was identified in the crude. An acid wash was used to separate 
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the starting material and the amide product to give a crude yield of 39% of the two 
isomeric products. Again, use of freshly re-crystallized N-phthalylglycyl chloride resulted 
in a reaction that gave total conversion by 1H NMR analysis. Purification by column 
chromatography gave a 60:40 mixture of dipeptides 124 and 125 in a yield of 48%. 
(Calculation of stereochemistry is discussed below) 
 
Given this encouraging starting point it was hoped to expand the reaction using a diverse 
range of more complex amino acids. All diallylated amino acid derivatives 111 were 
synthesized directly from the appropriate amino acid hydrochloride 126 by refluxing in 
acetronitrile with allyl bromide 127. (Scheme 37 and Table 6) 
  
   
Scheme 37: Synthesis of diallylated amino acid derivatives  
 
 
 
Table 6: Synthesis of di-allylated amino acid derivatives 
 
Entry Compound R Yield (%) 
1 111a (CH3)2CH- 70 
2 111b (CH3)2CH2CH- 61 
3 111c CH3CH2(CH3)CH- 69 
 
Rearrangements were then attempted, again using diisopropylethylamine, N-
phthalylglycyl chloride and ytterbium triflate as the Lewis acid catalyst. However, all 
attempts only returned the unreacted diallylated amino acid derivative and phthaloyl 
glycine. All the reactions were repeated using freshly prepared acyl chlorides and dried 
ytterbium triflate but again only starting materials were returned.   
 
The lack of the corresponding rearranged product was unexpected. The amino acids 
derivatives used were not radically different to diallylalanine methyl ester. Alanine 
derivative 123 had successfully undergone the desired [3,3] rearrangement. Valine, 
leucine and isoleucine have only a slight increase in the complexity of the carbon chain 
on the amino acid, with an extra three or four carbons on the chain terminus.  
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The reaction was then repeated with di-allyl isoleucine methyl ester, refluxing in DCM 
when the addition of the acyl chloride was complete. This again returned the di-allyl 
isoleucine methyl ester starting material and N-phthaloylglycine. The reaction was then 
repeated using dichloroethane as the solvent. After refluxing overnight this again 
returned only di-allyl isoleucine methyl ester starting material and N-phthaloylglycine. 
For avoidance of doubt, the reaction was performed in DCE with di-allyl alanine methyl 
ester 123 that gave the expected dipeptide product in 45% yield and a 
diastereoisomeric ratio of 60:40. 
 
The last amino acid variant tried was N-allyl proline methyl ester 129. The mono-
allayted variant of L-proline proved challenging to synthesize at first. Using the previous 
allyl bromide/sodium hydrogen carbonate conditions with one equivalent of allyl bromide 
produced a mixture of diallylated quaternary ammonium 130 and the desired N-allyl 
proline methyl ester 129 (Scheme 38). This mixture of products resulted in a very 
inefficient conversion to the desired product.  
 
 
 
Scheme 38: First attempt of synthesis of N-allyl proline methyl ester 
 
Repeating the reaction at room temperature in DMF proved significantly more selective, 
giving only the desired mono-allyl product 129. Purification by flash chromatography 
gave the product in 46% yield. 
 
 
Scheme 39: Belluš-Claisen Rearrangement of allyl proline methyl ester 
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Using the same base, ketene precursor and Lewis acid for the reaction, the 
rearrangement successfully proceeded to give the expected dipeptides 131 and 132 
(Scheme 39). The diastereoselectivity of the reaction was significantly better than when 
using alanine, giving a 75:25 ratio.  
 
Removal of impurities proved straightforward, with flash column chromatography giving 
a pure mixture of diastereomeric products. However, separation of the major and minor 
diastereomers proved challenging due to the almost identical rate of elution of the two 
isomers. HPLC was investigated as a possible method of purification but did not give 
sufficient separation of the diastereomers. A drastic increase in silica used (100g silica 
per gram product) finally produced diastereomerically enriched samples. Following 
controlled crystallization with a combination of IPA and tert-butyl ether gave dipeptide 
131 in sufficient purity to allow X-ray crystallography (Figure 17). The rearrangement 
was therefore favouring the generation of an (R) stereocentre. 
 
 
 
Figure 17: X-ray data of (S)-methyl 1-((R)-2-(1,3-dioxoisoindolin-2-yl)pent-4-enoyl)pyrrolidine-
2-carboxylate 131 
 67 
 
 
 
[3,3]-Sigmatropic rearrangements proceed through highly ordered six membered 
transition states which allows for chirality transfer from a stereogenic centre. When the 
asymmetric centre is incorporated into the cyclic framework of the transition state chiral 
information can be transferred in a concise and predictable manner.80 Belluš et al. 
reported the first diastereoisomeric  reaction between allyl sulfide 133 and dichloro acyl 
chloride 134 (Scheme 40). The resulting zwitterionic intermediate 135 then underwent 
[3,3]-sigmatropic rearrangement to give silyl ester 136. The rearrangement is directed 
by substituent X. The resulting 1,3-diaxial repulsive interactions in the intermediate 
results in the stereochemistry of 136 being preferred.140  
 
 
Scheme 40: Diasteroselective Ketene-Claisen Rearrangement140 
  
When the asymmetric centre is outside the transition state framework it can be more 
difficult to achieve high enantioselectivity. For the ketene-Claisen reaction using N-allyl 
proline methyl ester 129 the resulting stereochemistry of the product is determined by 
two sequential steps. Firstly, the addition of nucleophiles to monosubstituted ketenes 
usually results in the formation of the (Z)-enolate 140 (Scheme 41).141 The LUMO 
(lowest unoccupied molecular orbital) of the ketene is the C=O * orbital and as a result, 
nucleophiles that react with the ketene would have to overcome substantial steric 
interactions with the substituents to form the (E)-enolate 138.142 Therefore, nucleophiles 
will prefer to attack opposite the substituent, resulting in (Z)-enolate formation.  
 
 
 
 
Scheme 41: Preference for (Z)-enolate formation in addition to mono-substituted ketene 
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The second step, the resulting carbon-carbon bond formation during the [3.3] 
rearrangement, will be influenced by the stereochemistry of the proline moiety of 
zwitterionic intermediate 141. The fused five membered ring will restrict the relative 
position asymmetric centre, increasing the difficulty of attacking one face of the 
molecule. This would favour pathway A (Scheme 42), giving the (R) stereocentre. 
 
  
Scheme 42: Preference for R stereochemistry 
 
 
Following the success with N-allyl proline we planned to synthesize a range of allylated 
proline variants 145 to see if the reaction could tolerate substitutions on the allyl chain. 
Making the allyl proline anolgues was straight forward. Replacing allyl bromide with a 
suitably substituted alkyl bromide 144 gave the desired products 145 in yields of 40-
62% (Scheme 43 and Table 7).  
  
Scheme 43: Synthesis of N-Allyl Proline Methyl Ester derivatives 
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Table 7: Synthesis of N-Allyl Proline Methyl Ester derivatives 
 
Entry Compound R1 R2 R3 Yield (%) 
1 145a Me H H 49 
2 145b Me Me H 62 
3 145c H H Me 53 
4 145d Et H H 55 
5 145e Ph H H 40 
6 145f CO2Me H H 59 
 
 
Once products 145 had been successfully synthesized, Belluš-Claisen rearrangements 
were attempted with them. The same reaction conditions were used with a 
stoichiometric amount of ytterbium triflate as the Lewis acid. The reaction proved robust 
to a variety of allyl anologues, giving the rearranged dipeptides predominately of 146 
and 147 in moderate to good yields (40-70 %) (Scheme 44 and Table 8). 
 
  
Scheme 44: Belluš-Claisen Rearrangement with N-Allyl Proline Methyl Ester derivatives  
 
Table 8: Belluš-Claisen rearrangement with N-Allyl Proline Methyl Ester derivatives 
Entry 
Major 
product R R1 R2 Yield (%) 
Ratio of 
dipeptides 146 
and 147 
1 146a Me H H 42 66:33 
2 146b Me Me H 40 54:46 
3 146c H H Me 49 75:25 
4 146d Et H H 70 78:22 
5 146e Ph H H 51 54:46 
6 146f CO2Me H H 47 54:46 
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Purification of these diasteriomeric mixtures again proved challenging. Given the time 
constraints of the project it was not possible to isolate samples of sufficient purity for X-
ray crystallography for all variants of the reaction. However, a sample of 147d was 
isolated that allowed crystal data to be collected (Figure 18). 
 
Figure 18: 147d 
 
 
Claisen type rearrangements will preferentially go through a chair-like transition state 
that will give the corresponding syn product (Scheme 45).97 This is favoured because it 
is typically lower in energy than that of the corresponding boat transition state. When a 
second asymmetric centre was created during the rearrangement (Table 8, Entries 1, 4-
6) the products were overwhelmingly two diastereomers, even though there are four 
possible products.  
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Scheme 45: Syn/anti control in Claisen type reactions 
 
 
 
2.2.2 Reaction Optimization 
 
2.2.2.1 Solvent Screen  
 
A solvent screen was carried out on the Belluš-Claisen reaction otherwise using the same 
conditions with N-allyl proline methyl ester. Polar protic solvents readily react with acyl 
chlorides to return carboxylic acids, thus a selection of non-polar and polar aprotic 
solvents was chosen (Scheme 46 and Table 9). Of those solvents tried, the reaction only 
went to completion in chlorinated solvents- chloroform and dichloroethane. Yield and 
selectivity were similar to DCM (Table 9, Entries 1-3). Diethyl ether is a common solvent 
for Belluš-Claisen type reactions, however some of the reagents used in the reaction 
were not soluble which almost certainly led to trace yields (Table 9, Entry 4). No 
conversion was observed when using highly polar solvents such as acetonitrile and DMF 
(Table 9, Entries 6 and 8). 
 
 
Scheme 46: Solvent Screen 
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Table 9:  Solvent Screens 
Entry Solvent Yield (%) Diastereoisomeric 
ratio 
1 DCM 44 75:25 
2 CHCl3 41 75:25 
3 DCE 42 75:25 
4 Et2O 0 - 
5 THF 0 - 
6 DMF 0 - 
7 DMSO 0 - 
8 MeCN 0 - 
9 EtOAc 0 - 
 
2.2.2.2 Base Screen  
 
For completeness, a base screen was performed to investigate the effect of the base 
used on the reaction (Scheme 47 and Table 10). Surprisingly of the tertiary amine bases 
only diisopropylethyl amine gave moderate conversion to the desired product. 
Triethylamine did result in poor conversion to the desired product but showed no 
improvement in diastereomeric selectivity. Pyridine, DMAP and DBU either gave trace 
amounts of product or failed to show any conversion. All inorganic bases used failed to 
show conversion. 
 
The results of the screen were showed no correlation to pKa values, although how 
hindered the base was did seem to correlate with how effective the conversion was.  
 
 
 
Scheme 47: Base Screen 
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Table 10:  Base Screens 
Entry Base pKa
143,144 Yield (%) Diastereomeric ratio 
1 iPr2EtN 10.75 51 75:25 
2 Et3N 10.75 18 75:25 
3 DBU 12 0 - 
4 DMAP 9.2 0 - 
5 Pyridine 5.2 0 - 
6 NaOH 15.7 0 - 
7 KOH  0 - 
8 NaHCO3  0 - 
 
The MacMillan group reported similar problems when they tried alternate bases and 
speculated that nucleophlic tertiary amines were catalyzing an alternate pathway to give 
a non-desired side product. Nucleophlic tertiary bases act as a catalyst in the formation 
of -lactones by dimerization of ketenes in a known process.124 This competing pathway 
could explain the generally poor yield with only hindered tertiary bases given any 
notable yield.   
 
 
Scheme 48: Tertiary amine catalyzed formation of -lactone 
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2.2.2.3 Lewis Acid Screen  
 
Preferably, a catalytic amount of Lewis acid could be used in the reaction. All reactions 
done until this point had used stoichiometric quantities of ytterbium triflate to drive the 
reaction to completion. Due to ytterbium triflate having a relatively high molecular mass 
(620 g/mmol), this made the problem significantly more pronounced because by mass it 
accounts for nearly 50% of the reaction mixture. A Lewis acid that could get the same 
yields with a far smaller loading would represent a major improvement. A screen of 
Lewis acids was attempted (Scheme 49 and Table 11). 
 
 
Scheme 49: Lewis Acid Screen 
 
 
 
 
Table 11: Lewis Acid Screens 
 
Entry Lewis acid Yield Ratio 
1 Yb(OTf)3 47 75:25 
2 TiCl4 17 80:20 
3 Cu(OTf)2 0 - 
4 TiCl4(THF)2 29 80:20 
5 FeCl3 0 - 
6 Fe(acac)3 0 - 
7 Mg(OTf)2 0 - 
8 Sm(OTf)3 0 - 
9 Ti(OiPr)4 0 - 
 
Most Lewis acids screened failed to give the desired rearranged products 131 and 132. 
Of the Lewis acids tried only titanium tetrachloride and titanium tetrachloride THF 
complex gave any of the desired dipeptides. Following on from this both ytterbium 
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triflate and titanium tetrachloride were screened again, this time using increasingly 
smaller sub-stoichiometric amounts (Scheme 50 and Table 12). 
 
 
Scheme 50: Lewis Acid Loading Screen 
 
 
 
Table 12: Catalyst loading screen 
 
Entry Lewis acid Stochiometry Yield (%) Ratio 
1 Yb(OTf)3 100 49 75:25 
2 Yb(OTf)3 50 26 75:25 
3 Yb(OTf)3 25 0 - 
4 Yb(OTf)3 10 0 - 
5 TiCl4 50 27 80:20 
6 TiCl4 25 25 80:20 
7 TiCl4 10 19 80:20 
8 TiCl4(THF)2 50 34 75:25 
9 TiCl4(THF)2 25 29 75:25 
10 TiCl4(THF)2 10 17 75:25 
 
The failure of the reaction when a sub-stoichiometric amount of ytterbium triflate was 
used was cause for concern. The Lewis acid should be able to act as a catalyst in the 
reaction, being recycled after addition to the ketene and the subsequent rearrangement.  
The fact that a stoichiometric amount was needed strongly suggests that the Lewis acid 
was failing to dissociate from the amide after the rearrangement or that it was being 
poisoned in the reaction. In either case, the catalyst was failing to turnover. Conversely, 
both TiCl4 and TiCl4(THF)2 were found to still be effective at sub-stoichiometric amounts. 
Indeed, there was a small improvement in yield against using titanium tetrachloride in 
stoichiometric amounts. However, the overall yield of the reactions remained low.  
 
 76 
 
2.2.3 Temperature Control 
 
Further attempts to improve the reaction were employed by investigating the effects of 
temperature. It was hoped that:- 
1. an increase in selectivity could be achieved by using sub zero temperatures 
or 
2. heating would allow either less Lewis acid to be used or would be able to force re-
arrangements to occur that had failed at room temperatures. 
 
2.2.3.1 Conventional Method  
 
Typically the reaction was run at room temperature and went to completion within 4 
hours. Some experiments were attempted with various temperature gradients. The 
reaction was attempted at -78 ˚C in the hope that a significantly lower temperature 
would increase the stereo control of the reaction.  
 
A modest increase of the ratio of diastereomers was seen, going from 75:25 to 80:20. 
This was accompanied by a drastic reduction in conversion. Analysis of the crude mixture 
revealed that the reaction had not gone to completion and after purification an overall 
yield of only 17% was obtained. The reaction was repeated with cooling only during the 
addition of N-phthaloylglycyl chloride. After this, it was allowed to warm to room 
temperature and stirred for an additional 24 hours. 1H NMR analysis of the crude mixture 
showed an improvement in conversion but nonetheless 47% of the starting material 
remained. The drastic reduction in yield was not worth the slight increase in stereo-
control and further attempts were abandoned. 
 
2.2.3.2 Microwave 
 
Following the successful use of the microwave to perform aminations of anhydrouridine, 
it was hoped to apply the same chemistry to the Belluš Claisen rearrangement. 
 
The reaction has been successfully performed with alanine and various allylated proline 
variants. Unfortunately, attempts to expand the chemistry beyond these reactions have 
had limited success. Any allylated amino acids with more complicated side chains than 
alanine failed to rearrange at all, returning only starting material. Further, attempts to 
use stoichiometric quantities of ytterbium catalyst were also unsuccessful. 
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It was hoped that higher temperatures and greater pressures achievable by the 
microwave would provide sufficient activation energy to enable the reaction to work 
successfully. 
 
As a starting point, the successful N-allyl proline methyl ester rearrangement would be 
performed in the microwave. It takes the reaction at least 4 hours under conventional 
conditions, including a slow 2 hour addition step. It was hoped that simply performing 
this reaction in the microwave would, at a minimum, speed up the reaction. If it could be 
successfully performed then other amino acids would be attempted. 
 
Table 13 summarizes the result of this line of investigation. Because the reactions were 
performed in DCM, the microwave allowed dramatically higher temperatures than would 
be possible using conventional conditions. Ultimately, very high temperatures were 
necessary to drive the reaction to completion in a short time frame. Interestingly, higher 
temperatures seemed to have no effect on the stereo-control of the reaction, with a 
75:25 ratio of diastereoisomers still being obtained in all cases. 
 
 
Scheme 51: Microwave Irradiation Screen of Reactions 
 
 
Table 13: Microwave N-allyl proline methyl ester rearrangement  
 
Reaction Time 
(min) 
Temperature 
(˚C) 
Yield (%) Ratio 
10 80 0 - 
10 90 0 - 
20 90 0 - 
30 90 0 - 
30 100 <5  
60 120 21 75:25 
30 140 37 75:25 
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Despite the acyl chloride being added to the reaction mixture in one portion, it is worth 
noting that no [2+2] cyclisation products were observable in the reaction mixture. The 
Belluš Claisen reaction typically requires a controlled addition of the acyl chloride to the 
reaction mixture as the formation of [2+2] side products from the ketene are a serious 
detriment to the reaction124. It is probable that the phthaloyl protecting group is simply 
so bulky that it is preventing the [2+2] side reaction from occurring. This is also 
supported by the fact that the major side products observable by 1H NMR in failed 
reactions were the unreacted allylated amino acid derivative and N-phthaloyl glycine. No 
cycloadduct was seen in any reaction mixture. 
 
2.2.3.3 Ring Closing Metathesis 
 
Separation of the diastereoisomer mixtures produced during the Belluš-Claisen 
rearrangement, while not impossible, proved to be very difficult. Besides very time 
consuming purification methods, one idea investigated was the chemical transformation 
of un-separated mixtures to aid in purification. Dipeptides 114 and 115, produced from 
N,N-diallyl alanine methyl ester, are perfectly set up for a ring closing metathesis 
(Scheme 52).     
 
 
Scheme 52: Ring closing metathesis of dipeptides 114 and 115 
 
The reaction proved straightforward, with 2nd Generation Grubbs145 catalyst giving the 
expected product 159 on the first attempt in good yield (87%). It had been hoped that 
the increased rigidity of the seven membered ring would help to differentiate the 
products, making column chromatography easier. Unfortunately this was not the case 
because the mixtures were not any easier to separate than the original dipeptide.  
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2.3 Conclusions and Future Work 
 
A Belluš-Claisen rearrangement carried out with dimethylallylamine 109 with N-
phthaloylglycyl chloride 108 as the ketene precursor has been initially investigated and a 
method developed to synthesise 2-phthaloyl-N,N-dimethylpent-4-enamide 110. Out of a 
variety of Lewis acid catalysts so far tried, it has been found that anhydrous ytterbium 
triflate catalyst gives the best yield. 
 
The rearrangement has been attempted with a variety of allyated amino acids. N,N- 
diallyl alanine methyl ester 123 and N-allyl proline methyl ester 129 both gave 
successful rearrangements. Use of N-allyl proline in particular was found to result in a 
moderately diastereospecific methodology. However, attempts to repeat the reaction 
with structurally more complex amino acids did not result in successful rearrangements. 
Further optimisation of the reaction is required to improve the diastereoselectivity of the 
reaction.  
 
2.4 Experimental 
 
Reagents were purchased from Sigma-Aldrich, Acros, Alfa Aesar, Fisher Scientific, TCI 
UK or Lancaster Research Chemicals and were not purified except where stated.  
Solvents were purchased anhydrous and stored over molecular sieves, or distilled under 
nitrogen from an appropriate drying agent.  THF and diethylether were distilled from 
sodium benzophenone ketyl radical while DCM and acetonitrile were distilled from 
calcium hydride. Thin layer chromatography was performed on aluminum sheets coated 
with Merck silica gel 60 F254 with visualisation using potassium permanganate solution 
and/or scrutinised under 254 nm UV light. Column chromatography was performed using 
Silica 60 (35-70 microns) supplied by Fisher.  
 
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker Advance 
400 NMR spectrometer (1H NMR at 400 MHz, 13C NMR at 100 MHz) with the appropriate 
deuterated solvent.  Chemical shifts in 1H NMR spectra are expressed as ppm downfield 
from TMS and in 13C NMR, are relative to internal standard, and reported as singlet (s), 
doublet (d), triplet (t), quartet (q) and combinations thereof, or multiplet (m).  Coupling 
constants (J) are quoted in Hz and are rounded to the nearest 0.5 Hz.  Mass 
spectrometry was performed using a Bruker MicroTOF-Q instrument with electrospray 
ionisation in the positive mode.  FT-IR data was acquired using Thermo Electron 
Corporation Nicolet 380 FTIR with Smart Orbit diamond window instrument with 
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wavenumbers being reported in cm-1.  All melting points were obtained using a Stuart 
SMP10 melting point instrument. Microwave reactions were performed using a Milestone 
MicroSYNTH reactor and SK10 vessel containing one magnetic stirring bead. Twist 
control, rotor control, start parameters and continuous power were all selected. T1 
control was used with 60 % stirring.  
 
 
2.4.1  N-Phthaloylglycyl Chloride 108 131 
 
 
 
N-Phthaloylglycine (7.0 g, 34.1 mmol) was refluxed in thionyl chloride (19.6 g, 12 ml,  
164.5 mmol) for 1 hour. The solution was then concentrated in vacuo and the remaining 
residue was distilled at 110˚C /0.7mm (corrected boiling point of 320 ˚C at 760 mm) 
which, on cooling, gave a colourless solid. (6.0 g, 27.1 mmol, 79%) mp = 83-85 ˚C. (lit 
84-85 ˚C). Lit. boiling point 190-192 ˚C /15 mm (corrected boiling point of 320 ˚C at 
760 mm).  
 H (400 MHz, CDCl3), 4.15 (2H, s, NCH2), 7.77 (2H, m, Ar-H), 7.86 (2H, m, Ar-H). C(100 
MHz, CDCl3), 38.4 (NCH2), 123.5 (Ar-C), 132.0 (Ar-C), 134.2 (Quat. Ar-C), 167.6 (NCO), 
169.2 (COCl).max (thin film, cm-1), 2978 (C-H), 2938 (C-H), 1802 (COCl), 1768 and 
1710 (CONCO); m/z (ES+) calculated for C10H7O4N (hydrolysed product) [M+H]
+; 
206.0448. found 206.0453. 
 
2.4.2  N-Tosylglycine 121146  
 
 
 
Glycine (2.60g, 30.0 mmol, 1.0 eq) was dissolved in 50 mL of 1.5M NaOH at room 
temperature and p-toluenesulfonyl chloride (6.80 g, 36.0 mmol, 1.2 eq) in Et2O (30 mL) 
was added. After leaving to stir overnight 6M HCl was be added until pH = 2. The Et2O 
layer was separated and the aqueous layer was extracted with Et2O (3 x 40 mL). The 
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combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo to 
give the product. Recrystallization from Et2O gave the product as a white powder (2.91 
g, 11.8 mmol, 39%). Mp = 146-149 ˚C. lit 147.6 ˚C. 
 H (400 MHz, (CD3)2CO), 2.27 (3H, s, CH3), 3.64 (2H, d, J = 6.0 Hz, CH2), 6.52 (1H, t, J 
= 6.0 Hz, NH), 7.25 (2H, d, J = 8.0 Hz, Ar-H), 7.63 (2H, d, J = 8.0 Hz, Ar-H). C (100 
MHz, CDCl3), 20.5 (CH3), 43.7 (CH2), 127.0 (Ar-C), 129.5 (Ar-C), 137.9 (Quat. Ar-C), 
143.1 (Quat. Ar-C), 169.5 (COOH).max (thin film, cm-1), 3353 (C-H), 1709 (CO); m/z 
(ES+) calculated for C9H11SO4N [M+H]
+; 230.0482. found 230.0485. 
 
2.4.3 N-Tosylglycyl Chloride 122139 
 
 
N-Tosylglycine (2.48g, 10.0 mmol, 1.0 eq) was dissolved in Et2O (25 mL) and  PCl5 
(3.09g, 15.0 mmol, 1.5 eq) was added. The reaction was left to stir for 30 minutes until 
all organic material has dissolved. The reaction was then allowed to stir for a further 30 
minutes. Excess PCl5 was removed by filtration and hexane (100 mL) was added. The 
solution was set aside at 0˚C for four hours. 
 
The crystalline acid chloride will then be filtered off, washed with hexane and dried under 
vacuum to give the product as a colourless solid (1.59 g, 6.42 mmol, 64%) mp = 81-85 
˚C. Lit 82-83˚C. 
 H (400 MHz, CDCl3), 2.44 (3H, s, CH3), 4.27 (2H, s, CH2), 5.25 (1H, br s, NH), 7.34 (2H, 
d, J = 8.0 Hz, Ar-H), 7.75 (2H, d, J = 8.0 Hz, Ar-H). C (100 MHz, CDCl3), 21.6 (CH3), 
53.6 (CH2), 127.1 (Ar-C), 130.0 (Ar-C), 136.1 (Quat. Ar-C), 144.5 (Quat. Ar-C), 171.0 
(COOH).max (thin film, cm-1), 2980 (C-H), 1802 (COCl). 
 
2.4.4 General Belluš-Claisen Procedure 
 
Modifying a procedure by MacMillan et al122, to a solution of dried Yb(OTf)3 (1.0 eq) in 
dry DCM (20 mL) was added N,N-dimethylallylamine (1.0 eq) followed by N,N-
diisopropylethylamine (2.0 eq). The solution was stirred for 5 min before a solution of N-
phthaloylglycyl chloride (1.5 eq) in dry DCM (10 mL) was added drop-wise over 2 hours. 
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The resulting dark orange mixture was then stirred for an additional 2 hours. The 
reaction was then diluted with diethyl ether (20 mL), treated with aqueous NaOH (1M; 
10 mL) and stirred for a further 10 minutes. The aqueous layer was extracted with 
diethyl ether (3 x 40 mL) and the organic layers combined, washed with brine (3 x 20 
mL), and dried over Na2SO4, filtered and concentrated in vacuo. Purification by column 
chromatography and/or re-crystalization gave the desired product 
 
2.4.5 2-Phthaloyl-N,N-dimethylpent-4-enamide 110  
 
 
 
 
Following general Belluš Claisen procedure from dried Yb(OTf)3 (1.24 g, 2.00 mmol, 1.0 
eq), N,N-dimethylallylamine (170 mg, 0.24 mL, 2.00 mmol, 1.0 eq), N,N-
diisopropylethylamine (517 mg, 0.70 mL, 4.00 mmol, 2.0 eq) and N-phthaloylglycyl 
chloride (670 mg, 3.00 mmol, 1.5 eq) 2-phthaloyl-N,N-dimethylpent-4-enamide was 
obtained as a yellow oil that solidified on standing. This was recrystallised from IPA/tert-
butyl methyl ether to give the product as a pale yellow solid. (311 mg, 1.14 mmol, 57%) 
mp = 106-107 ˚C. 
 H (400 MHz, CDCl3), 2.76-2.83 (1H, app m, CH2), 2.98 (6H, s, CH3), 3.12-3.20 (1H, app 
m, J = 10.5 Hz, CH2), 5.00 (1H, app d, J = 10.0 Hz, NCH), 5.07-5.12 (2H, app m, trans 
CH=CH2, CH), 5.78 (1H, dddd, J = 4.0 Hz, J = 5.5 Hz, J = 10.0 Hz, J = 17.0 Hz, 
CH=CH2), 7.71-7.76 (2H, m, C=CH), 7.83-7.87 (2H, m, C=CH-CH). C (100 MHz, CDCl3), 
33.4 (NCHCH2), 36.3 (NCH3), 37.0 (NCH3), 51.1 (NCHCO), 118.7 (CH=CH2), 123.5 (Ar-
C), 131.5 (Quat. Ar-C), 133.7 (CH2=CH), 134.2 (Ar-C), 167.8 (NCO), 168.1 (CON(CH3)2. max (thin film, cm-1), 2965 (C-H), 1716 (Ester CO2), 1387 (C-H); m/z (ES+) calculated 
for C15H16O3N2 [M+H]
+; 273.1234. found 273.1246. 
 
2.4.6 General Diallylation Procedure 147 
 
Amino methyl ester hydrochloride (1.0 eq) was added to a mixture of allyl bromide 
(2.2eq) and sodium hydrogen carbonate (4.0 eq) in acetronitrile (40 mL). The reaction 
was heated to 70 oC and left to stir overnight under nitrogen. After 18 hours the reaction 
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was cooled to room temperature and the resulting precipitated salt removed by filtration. 
The mixture was then concentrated in vacuo to give the crude product which was 
purified by column chromatography (ethyl acetate) to give the product. 
 
2.4.7  N,N-Diallyl alanine methyl ester 123147 
 
 
 
Following N-allylation procedure from L-alanine methyl ester hydrochloride (2.00g, 14.3 
mmol, 1.0 eq), allyl bromide (3.81g, 2.73 mL, 31.5 mmol, 2.2 eq) and sodium hydrogen 
carbonate (4.81g, 57.3 mmol, 4.0 eq) N,N-diallyl alanine methyl ester was obtained as a 
pale yellow oil (1.89 g, 10.3 mmol, 72%). 
 H (400 MHz, CDCl3), 1.26 (3H, d, J = 7.0, CHCH3), 3.13 (2H, ddt, J = 1.0, J = 7.0, J = 
14.5 Hz, NCHAHB), 3.26 (2H, ddt, J = 1.5, J = 5.5, J =14.5 Hz, NCHAHB), 3.60 (1H, q, J 
= 7.0 Hz, CHCH3), 3.69 (3H, s, OCH3), 5.10 (2H, ddd, J = 1.0, J = 3.0, J = 10.0 Hz, cis 
CH=CH2), 5.19 (2H, ddd, J = 1.5, J = 3.0, J = 17.0 Hz, trans CH=CH2), 5.80 (2H, dddd, 
J = 5.0, J = 7.0, J = 10.0, J = 17.0, CH2=CH). C (100 MHz, CDCl3), 14.6 (CHCH3), 51.1 
(OCH3), 53.4 (NCH2), 57.1 (CH), 117.0 (CH=CH2), 136.4 (CH=CH2), 174.2 (CO). m/z 
(ES+) calculated for C10H17NO2 [M+H]
+; 184.1332. found 184.1339. 
 
2.4.8  N,N-Diallyl isoleucine methyl ester 111c 
 
 
 
Following N-allylation procedure from L-isoleucine methyl ester hydrochloride (2.0g, 11.0 
mmol, 1.0 eq), allyl bromide (2.93g, 2.10 mL, 24.2 mmol, 2.2eq) and sodium hydrogen 
carbonate (3.70g, 44.0 mmol, 4.0 eq) N,N-diallyl isoleucine methyl ester was obtained 
as a pale yellow oil. (1.89 g, 8.25 mmol, 75%) 
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H (400 MHz, CDCl3), 0.81 (3H, d, J = 6.5 Hz, CHCH3), 0.85 (3H, t, J = 7.5 Hz, CH2CH3), 
1.10-1.17 (1H, m, CH3CH
AHB), 1.66-1.80 (1H, m, CH3CH
AHB), 1.81-1.93 (1H, m, 
NCHCH), 2.82 (2H, app dd, J = 8.0, J = 14.5 Hz, NCHAHB), 3.09 (1H, d, J = 11.0 Hz, 
NCH), 3.41 (2H, app dt, J = 2.0, J =14.5 Hz, NCHAHB), 3.69 (3H, s, OCH3), 5.09 (2H, 
app d, J = 10.0 Hz, cis CH=CH2), 5.18 (2H, app d, J = 17.0 Hz, trans CH=CH2), 5.75 
(2H, dddd, J = 4.5, J = 9.0, J = 10.0, J = 17.0 Hz, CH2=CH). C (100 MHz, CDCl3), 10.1 
(CH2CH3), 15.9 (CHCH3), 24.8 (CH3CH2), 33.2 (NCHCH), 50.5 (OCH3), 53.3 (NCH2), 67.0 
(NCH), 116.9 (CH=CH2), 136. 6 (CH=CH2), 173.0 (CO). m/z (ES
+) calculated for 
C13H23NO2 [M+H]
+; 226.1802. found 226.1812. 
 
2.4.9 N,N-Diallyl valine methyl ester 111a 
 
Following N-allylation procedure from L-valine methyl ester hydrochloride (2.0g, 11.9 
mmol, 1.0 eq), allyl bromide (3.18g, 2.27 mL, 26.2 mmol, 2.2eq) and sodium hydrogen 
carbonate (4.01g, 143.3 mmol, 4.0 eq) N,N-diallyl valine methyl ester was obtained as a 
yellow oil. (1.53 g, 7.26 mmol, 61%) 
 H (400 MHz, CDCl3), 0.85 (3H, d, J = 6.5 Hz, CHCH3), 0.96 (3H, d, J = 6.5 Hz, CHCH3), 
1.98-2.07 (1H, m, (CH3)2CH), 2.83 (2H, app dd, J = 8.0, J = 15.0 Hz, NCH
AHB x 2), 2.96 
(1H, d, J = 11.0 Hz, CHCO), 3.41 (2H, ddt, J = 2.0, J = 4.0, J = 15.0 Hz, NCHAHB x 2), 
3.69 (3H, s, OCH3), 5.10 (2H, dd, J = 2.0, 10.0 Hz, cis CH=CH2), 5.19 (2H, ddd, J = 1.0, 
2.0, 17.0 Hz, trans CH=CH2), 5.75 (2H, dddd, J = 4.0, J = 8.0, J = 10.0, J = 17.0 Hz, 
CH2=CH). C (100 MHz, CDCl3), 19.5 (CHCH3), 19.9 (CHCH3), 27.6 (CH(CH3)2), 50.6 
(OCH3), 53.3 (NCH2), 68.8 (NCH), 116.8 (CH=CH2), 136.6 (CH=CH2), 173.0 (CO). m/z 
(ES+) calculated for C12H21NO2 [M+H]
+; 212.1645. found 212.1655. 
 
2.4.10 N,N-Diallyl leucine methyl ester 111b 147 
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Following N-allylation procedure from L-leucine methyl ester hydrochloride (2.0g, 11.0 
mmol, 1.0 eq), allyl bromide (2.93g, 2.10 mL, 24.2 mmol, 2.2eq) and sodium hydrogen 
carbonate (3.70g, 44.0 mmol, 4.0 eq) N,N-diallyl leucine methyl ester was obtained as a 
yellow oil. (1.69 g, 7.48 mmol, 68%) 
 H (400 MHz, CDCl3), 0.87 (3H, d, J = 6.5 Hz, CHCH3), 0.90 (3H, d, J = 6.5 Hz, CHCH3), 
1.46-1.60 (2H, m, CHCH2), 1.65-1.73 (1H, m, CH(CH3)2), 3.03 (2H, app dd, J = 7.5, J = 
14.5 Hz, NCHAHB), 3.35 (2H, ddt, J = 1.5, J = 4.5, J = 14.5 Hz, NCHAHB), 3.52 (1H, dd, J 
= 7.0, J = 8.0 Hz, CHCO), 3.68 (3H, s, OCH3), 5.10 (2H, app d, J = 10.0 Hz, cis 
CH=CH2), 5.18 (2H, app d, J = 17.0 Hz, trans CH=CH2), 5.72 (2H, dddd, J = 5.0, J = 
7.0, J = 10.0, J = 17.0 Hz, CH2=CH). C (100 MHz, CDCl3), 22.0 (CHCH3), 23.0 (CHCH3), 
24.6 (CH(CH3)2), 38.6 (NCHCH2), 50.9 (OCH3), 53.4 (NCH2), 59.9 (NCH), 117.0 
(CH=CH2), 136.7 (CH=CH2), 174.2 (CO). m/z (ES
+) calculated for C16H23NO2 [M+H]
+; 
226.1802. found 226.1811. 
 
2.4.11 General  Mono Allylation Procedure 
 
L-proline methyl ester hydrochloride (1.0 eq) was taken up in DMF (50 mL) and cooled 
to 0 ˚C. Allyl bromide (1.1 eq) was then added, followed by triethylamine (2.0 eq). The 
reaction was allowed to warm to room temperature and left to stir overnight under 
nitrogen. After 18 hours the reaction was quenched with H2O (50 mL) and extracted with 
EtOAc (40 mL x 3). The organic layers were combined, washed with H2O (30 mL x 3) 
and dried over Na2SO4, filtered and concentrated in vacuo to give the crude. The product 
was purified by column chromatography (90:10 hexanes: ethyl acetate) to give the 
product. 
 
2.4.12  N-Allyl proline methyl ester 129148 
 
 
Following mono N-allylation procedure from L-proline methyl ester hydrochloride (5.00g, 
30.2 mmol, 1.0 eq), allyl bromide (4.02g, 2.87 mL, 33.2 mmol, 1.1 eq) and 
triethylamine (6.11 g, 8.4 mL, 60.4 mmol, 2.0 eq) N-Allyl proline methyl ester was 
obtained as a pale yellow oil (2.61 g, 5.32 mmol, 44%). 
 86 
 
 H (400 MHz, CDCl3), 1.75-1.87 (1H, m, NCHCHH), 1.88-1.99 (2H, m, NCHCHH + NCH-
2CHH), 2.07-2.20 (1H, m, NCH2CHH), 2.38 (1H, q, J = 9.0 Hz, NCH), 3.09-3.19 (2H, m, 
CHCO + NCHH-CH=CH2), 3.31 (1H, app dd, J = 6.5, J = 13.0 Hz, NCHH-CH=CH2), 3.72 
(3H, s, OCH3), 5.09 (1H, dd, J = 1.0, J = 10.0 Hz, cis CH=CH2), 5.18 (1H, dd, J = 1.0, J 
= 17.0 Hz, trans CH=CH2), 5.92 (1H, ddt, J = 7.0, J = 10.0, J = 17.0 Hz, CH2=CH).C 
(100 MHz, CDCl3), 23.0 (NCHCH2), 29.5 (NCH2CH2), 51.8 (OCH3), 53.5 (NCH2CH2), 57.8 
(NCH2CH), 65.2 (CHCO), 117.4 (CH=CH2), 135.2 (CH=CH2), 174.6 (CO). max (thin film, 
cm-1), 2951 (C-H), 1732 (Ester CO2), 1435 (Alkene C-H), 1195 and 1167 (C-N); m/z 
(ES+), calculated for C9H15NO2 [M+H]
+; 170.1176. found 170.1193. 
 
2.4.13 (S)-Methyl 2-((R)-N-allyl-2-(1,3-dioxoisoindolin-2-yl)pent-
4-enamido)propanoate 124 
  
 
Following general Belluš Claisen procedure from dried Yb(OTf)3 (620 mg, 1.00 mmol, 1.0 
eq), N,N-diallylalanine methyl ester (183 mg, 1.00 mmol, 1.0 eq), N,N-
diisopropylethylamine (258 mg, 0.25 mL, 2.00 mmol, 2.0 eq and  N-phthaloylglycyl 
chloride (335 mg, 1.50 mmol, 1.5 eq) (S)-Methyl 2-((R)-N-allyl-2-(1,3-dioxoisoindolin-2-
yl)pent-4-enamido)propanoate was obtained as a yellow oil. Purification by column 
chromatography (diethyl ether) yielded the two diastereoisomers in a 60:40 ratio as a 
yellow oil. On standing overnight the oil solidified to give a pale yellow solid. (178 mg, 
0.48 mmol, 48%). mp = 82-86 ˚C. 
 H (400 MHz, CDCl3), 1.43 (3H, d, J = 7.0 Hz, Minor CHCH3), 1.49 (3H, d, J = 7.0 Hz, 
Major CHCH3), 2.78-2.81 (1H, m, CHCH
AHB), 3.06-3.22 (1H, m, CHCH
AHB), 3.69 (3H, s, 
Major OCH3), 3.72 (3H, s, Minor OCH3), 3.97 (2H, d, J = 5.0 Hz, NCH2), 4.14 (1H, q, J = 
7.0 Hz, Major CHCH3), 4.46 (1H, q, J = 7.0 Hz, Minor CHCH3), 4.88-5.30 (5H, m, 
CH=CH2 x 2, (CO)2NCH), 5.60-5.86 (2H, m, CH2=CH x 2), 7.71-7.75 (2H, m, Ar-H), 
7.81-7.85 (2H, m, Ar-H). C (100 MHz, CDCl3), (Major diastereoisomer), 14.6 (CHCH3), 
33.5 (CHCH2), 50.6 (NCH2), 51.0 (CHCH2), 52.2 (OCH3), 55.7 (CHCH3), 117.6 (CH=CH2), 
118.8 (CH=CH2), 123.5 (Ar-C), 131.7 (Quat. Ar-C), 133.0 (CH2=CH), 133.5 (CH2=CH), 
134.2 (Ar-C), 167.5 (N(CO)2), 168.9 (CH(CO)NCH), 171.8 (COCH3), (Minor 
diastereoisomer), 14.3 (CHCH3), 33.3 (CHCH2), 48.7 (NCH2), 54.9 (CHCH3), 117.0 
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(CH=CH2), 123.4 (Ar-C), 131.7 (Quat. Ar-C), 133.2 (CH2=CH), 133.5 (CH2=CH), 134.1 
(Ar-C), 168.9 (CH(CO)NCH), 171.8 (COCH3). max (thin film, cm-1), 2949 (C-H), 1709 
(Ester CO2), 1646 (Amide); m/z (ES
+) calculated for C20H22O5N2 [M+H]
+; 371.1601. 
found 371.1604. 
 
2.4.14 (S)-Methyl 1-((R)-2-(1,3-dioxoisoindolin-2-yl)pent-4-
enoyl)pyrrolidine-2-carboxylate 131 
 
   
 
Following general Belluš Claisen procedure from dried Yb(OTf)3 (1.24 g, 2.00 mmol, 1.0 
eq), N-Allyl proline methyl ester (338 mg, 2.00 mmol, 1.0 eq), N,N-
diisopropylethylamine (517 mg, 0.70 mL, 4.00 mmol, 2.0 eq) and N-phthaloylglycyl 
chloride (670 mg, 3.00 mmol, 1.5 eq) (S)-Methyl 1-((R)-2-(1,3-dioxoisoindolin-2-
yl)pent-4-enoyl)pyrrolidine-2-carboxylate was obtained as a yellow oil. Purification by 
column chromatography yielded the two diastereoisomers in a 75:25 ratio as a yellow 
oil.  (421 mg, 0.44 mmol, 59%). On standing overnight the product solidified as a yellow 
solid. Recrystalisation from diisopropylether/IPA isolated the major diasteriosmer as pale 
colourless crystals.  mp = 139-143 ˚C.  
 H (400 MHz, CDCl3), 1.83-2.03 (3H, m, NCHCHAHBCH2, NCH2CHAHB), 2.18-2.25 (1H, m, 
NCHCHAHBCH2), 2.85 (1H, dtt, J = 1.5, J = 5.5, J = 14.5 Hz, (CO)2NCHCH
AHB), 3.09 (1H, 
app dt, J = 9.5, J = 14.5 Hz, (CO)2NCHCH
AHB), 3.36-3.42 (1H, m, NCHAHBCH2), 3.56-
3.62, (1H, m, NCHAHBCH2), 3.70 (3H, s, OCH3), 4.54 (1H, dd, J = 6.0, J = 8.5 Hz, 
CHCONCH), 4.96-5.02 (2H, m, (CO)2NCH + CH=CH2 cis), 5.08 (1H, dd, J = 1.0, 17.0 Hz, 
CH=CH2 trans), 5.76 (1H, dddd, J = 5.5, J = 9.0, J = 10.0, J = 17.0 Hz, CH=CH2), 7.74 
(2H, dd, J = 3.0, J = 5.5 Hz, Ar-H), 7.88 (2H, dd, J = 3.0, J = 5.5 Hz, Ar-H). C (100 
MHz, CDCl3), 25.3 (NCHCH2CH2), 28.8 (NCH2CH2), 33.0 (CH2CH=CH2), 47.0 (NCH2CH2), 
51.9 ((CO)2NCH), 52.2 (OCH3), 59.6 (CONCHCO), 118.8 (CH=CH2), 123.6 (Ar-C), 131.5 
(Quat. Ar-C), 133.5 (CH2=CH), 134.2 (Ar-C), 166.9 (CH(CO)NCH), 167.3 (N(CO)2), 
172.1 (COCH3). max (thin film, cm-1), 2980 (C-H), 1381 (C-H); m/z (ES+) calculated for 
C15H17O3N2 [M+H]
+; 273.12. found 273.12. 
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2.4.15 (S)-Methyl 1-((S)-2-(1,3-dioxoisoindolin-2-yl)pent-4-
enoyl)pyrrolidine-2-carboxylate 132 
 
 
 H (400 MHz, CDCl3), 1.88-2.13 (4H, m, NCHCHAHBCH2, NCH2CHAHB), 2.89 (1H, dtt, J = 
1.5, J = 5.5, J = 14.5 Hz, (CO)2NCHCH
AHB), 3.13 (1H, app dt, J = 9.5, J = 14.5 Hz, 
(CO)2NCHCH
AHB), 3.30-3.37 (1H, m, NCHAHBCH2), 3.66-3.71, (1H, m, NCH
AHBCH2), 3.74 
(3H, s, OCH3), 4.50 (1H, dd, J = 6.0, J = 8.5 Hz, CHCONCH), 5.00-5.06 (2H, m, 
(CO)2NCH + CH=CH2 cis), 5.09 (1H, app dq, J = 1.0, 17.0 Hz, CH=CH2 trans), 5.78 (1H, 
dddd, J = 5.5, J = 9.0, J = 10.0, J = 17.0 Hz, CH=CH2), 7.74 (2H, dd, J = 3.0, J = 5.5 
Hz, Ar-H), 7.85 (2H, dd, J = 3.0, J = 5.5 Hz, Ar-H). C (100 MHz, CDCl3), 24.9 
(NCHCH2CH2), 28.7 (NCH2CH2), 33.0 (CH2CH=CH2), 46.9 (NCH2CH2), 52.3 ((CO)2NCH), 
52.3 (OCH3), 59.4 (CONCHCO), 118.7 (CH=CH2), 123.6 (Ar-C), 131.5 (Quat. Ar-C), 
133.6 (CH2=CH), 134.2 (Ar-C), 167.1 (CH(CO)NCH), 167.7 (N(CO)2), 172.5 (COCH3). 
 
2.4.16 N-Crotyl L-proline methyl ester 145a 
 
 
 
Following mono N-allylation procedure from L-Proline methyl ester hydrochloride (2.00g, 
12.1 mmol, 1.0 eq), crotyl bromide (1.80g, 1.37 mL, 13.3 mmol, 1.1 eq) and 
triethylamine (2.47 g, 3.40 mL, 24.2 mmol, 2.0 eq) N-Crotyl L-proline methyl ester was 
obtained as a mix of cis and trans products as a pale yellow oil (1.09 g, 5.93 mmol, 
49%). 
 H (400 MHz, CDCl3), 0.97 (3H, d, J = 7.5 Hz, CHCH3), 1.66-1.78 (1H, m, NCHCHAHB), 
1.79-1.82 (2H, m, NCHCHAHB + NCH2CH
AHB), 1.88-1.97  2.09-2.16 (1H, m, NCH2CH
AHB),  
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2.35 (1H, app q, J = 9.0 Hz, NCHAHBCH2), 3.06–3.17 (4H, m, NCHAHBCH2, NCH2CH, 
CHCO), 3.71 (3H, s, OCH3), 5.50-5.63 (2H, m, CH=CHCH3, CH=CHCH3).C (100 MHz, 
CDCl3), 17.7 (CHCH3), 23.0 (NCHCH2), 29.5 (NCH2CH2), 51.8 (OCH3), 53.5 (NCH2CH2), 
56.9 (NCH2CH), 65.3 (CHCO), 127.8 (CH3CH=CH), 128.8 (CH3CH=CH), 174.8 (CO). max 
(thin film, cm-1), 2951 (C-H), 1732 (Ester CO2), 1435 (Alkene C-H), 1195 and 1168 (C-
N); m/z (ES+), calculated for C10H17NO2 [M+H]
+; 184.1332. found 184.1339. 
 
2.4.17 N-(2-Methylprop-2-en-1-yl)-L-proline methyl ester 145c 
 
 
 
Following mono N-allylation procedure from L-Proline methyl ester hydrochloride (2.00g, 
12.1 mmol, 1.0 eq), 1-bromo-2-methylpropene (1.80 g, 1.37 mL, 13.3 mmol, 1.1 eq) 
and  triethylamine (2.47 g, 3.40 mL, 24.2 mmol, 2.0 eq) N-(2-Methylprop-2-en-1-yl)-L-
proline methyl ester was obtained as a pale yellow oil. (1.16 g, 6.41 mmol, 53%) 
 H (400 MHz, CDCl3), 1.78 (3H, s, CCH3), 1.75-1.86 (1H, m, NCHCHAHB), 1.87-2.00 (2H, 
m, NCHCHAHB + NCH2CH
AHB), 2.09-2.18 (1H, m, NCH2CH
AHB), 2.35 (1H, app q, J = 8.0 
Hz, 1H, m, NCHAHBCH2), 2.96 (1H, d, J = 12.5 Hz, NCH
AHB-CH=CH2), 3.05-3.10 (1H, m, 
NCHAHBCH2), 3.19 (1H, dd, J = 5.5, J = 9.0 Hz, CHCO), 3.22 (1H, d, J = 12.5 Hz, 
NCHAHB-CH=CH2), 3.70 (3H, s, OCH3), 4.79 (1H, s, cis C=CH2), 4.86 (1H, s, trans 
C=CH2).C (100 MHz, CDCl3), 20.8 (CCH3), 23.1 (NCHCH2), 29.4 (NCH2CH2), 51.6 
(OCH3), 53.5 (NCH2CH2), 61.7 (CH2-C=CH), 65.6 (CHCO), 112.7 (C=CH2), 143.6 
(C=CH2), 174.8 (CO). max (thin film, cm-1), 2951 (C-H), 1732 (Ester CO2), 1435 (Alkene 
C-H), 1195 and 1167 (C-N); m/z (ES+) calculated for C10H17NO2 [M+H]
+; 184.1332. 
found 184.1346. 
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2.4.18  N-(3-Methylbut-2-enyl)-L-proline methyl ester 145b 
 
 
 
 
Following mono N-allylation procedure from L-Proline methyl ester hydrochloride (2.00g, 
12.1 mmol, 1.0 eq), 3,3-dimethylallyl bromide (1.98g, 1.53 mL, 13.3 mmol, 1.1 eq) and 
triethylamine (2.47 g, 3.40 mL, 24.2 mmol, 2.0 eq) N-(3-Methylbut-2-enyl)-L-proline 
methyl ester product as a pale yellow clear oil. (1.48 g, 7.50 mmol, 62%) 
 H (400 MHz, CDCl3), 1.65 (3H, s, cis CH3), 1.71 (3H, d, J = 1.0 Hz trans CH3), 1.71-1.83 
(1H, m, NCHCHAHB), 1.88-1.97 (2H, m, NCHCHAHB, NCH2CH
AHB), 2.05-2.17 (1H, m, 
NCH2CH
AHB), 2.36 (1H, app q, J = 8.0 Hz, 1H, m, NCHAHBCH2), 3.09 (1H, dd, J = 7.0, J 
= 13.0 Hz, NCHAHBCH=C), 3.11-3.20 (2H, m, CHCO, NCHAHBCH2), 3.27 (1H, dd, J = 7.5, 
J = 13.0 Hz, NCHAHBCH=C), 3.71 (3H, s, OCH3), 5.29 (1H, app tquin, J = 1.0 , J = 7.0 
Hz, C=CH).C (100 MHz, CDCl3), 17,8 (cis CH3), 23.0 (NCHCH2), 25.8 (trans CH3), 29.4 
(NCH2CH2), 51.8 (OCH3), 51.8 (NCH2CH=C), 53.5 (NCH2CH2), 65.4 (CHCO), 121.0 
(CH2CH=C), 135.1 (CH2CH=C), 174.8 (CO). max (thin film, cm-1), 2951 (C-H), 1732 
(Ester CO2), 1435 (Alkene C-H), 1193 and 1167 (C-N); m/z (ES
+) calculated for 
C15H19NO2 [M+H]
+; 198.1489. found 198.1510. 
 
2.4.19  N-Cinnamyl-L-proline methyl ester 145e 
 
 
 
 
Following mono N-allylation procedure from L-Proline methyl ester hydrochloride (5.00g, 
30.3 mmol, 1.0 eq) cinnamyl bromide (6.55g, 33.3 mmol, 1.1 eq) and triethylamine 
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(6.18 g, 8.51 mL, 60.5 mmol, 2.0 eq) N-Cinnamyl-L-proline methyl ester was obtained 
as an orange oil. (4.31 g, 17.6 mmol, 40%) 
 H (400 MHz, CDCl3), 1.74-1.86 (1H, m, NCHCHAHB), 1,88-2.01 (2H, m, NCHCHAHB, 
NCH2CH
AHB), 2.07-2.20 (1H, m, NCH2CH
AHB), 2.41 (1H, app q, J = 8.5 Hz, 1H, 
NCHAHBCH2), 3.16-3.23 (2H, m, NCH
AHBCH2, CHCO), 3.30 (1H, dd, J = 7.0, J = 13.0, 
NCHAHB-CH), 3.41 (1H, dd, J = 7.0, J = 13.5 Hz, NCHAHB-CH), 3.63 (3H, s, OCH3), 6.33 
(1H, app dt, J = 7.0 , J = 16.0 Hz, Ph-CH=CH), 6.50 (1H, d, J = 16.0 Hz, Ph-CH).C 
(100 MHz, CDCl3), 23.1 (NCHCH2), 29.6 (NCH2CH2), 51.8 (OCH3), 53.8 (NCH2CH2), 57.12 
(NCH2CH), 65.4 (CHCO), 126.3 (Ar-C), 126.8 (PhCH=CH), 127.4 (Ar-C), 128.5 (Ar-C), 
132.5 (PhCH=CH), 136.9 (Quat. Ar-C), 174.7 (NCHCO). max (thin film, cm-1), 2950 (C-
H), 1731 (Ester CO2), 1435 (Alkene C-H), 1195 and 1167 (C-N); m/z (ES
+) calculated 
for C15H19NO2 [M+H]
+; 246.1489. found 246.1511. 
 
2.4.20 N-(4-Methoxy-4-oxobut-2-en-1-yl)-L-Proline methyl ester 
145f 
 
 
 
 
Following mono N-allylation procedure from L-Proline methyl ester hydrochloride (1.00g, 
6.04 mmol, 1.0 eq), methyl trans-4-bromo-2-butenoate (1.19 g, 2.87 mL, 6.67 mmol, 
1.1 eq) and triethylamine (1.23 g, 1.69 mL, 12.1 mmol, 2.0 eq) N-(4-Methoxy-4-
oxobut-2-en-1-yl)-L-Proline methyl ester was obtained as a pale yellow oil. (810 mg, 
3.56 mmol, 59%) 
 H (400 MHz, CDCl3), 1.79-2.19 (3H, m, NCHCHAHB, NCHCHAHB, NCH2CHAHB), 2.09-2.19 
(1H, m, NCH2CH
AHB), 2.45 (1H, app q, J = 8.0 Hz, 1H, m, NCHAHBCH2), 3.12-3.17 (1H, 
m, NCHAHBCH2), 3.23-3.26 (1H, m, CHCO), 3.27 (1H, ddd, J = 1.5, J = 6.5, J = 15.0 Hz, 
NCHAHB-CH=CH2), 3.51 (1H, ddd, J = 1.5, J = 6.0, J = 15.0 Hz, NCH
AHB-CH=CH2), 3.71 
(3H, s, NCHC(O)OCH3), 3.73 (3H, s, CH=CHC(O)OCH3), 5.99 (1H, dt, J = 1.5 , J = 15.5 
Hz, cis C=CH2), 7.0 (1H, dt, J = 6.5, J = 15.5 Hz, trans C=CH2).C (100 MHz, CDCl3), 
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23.1 (NCHCH2), 29.3 (NCH2CH2), 51.4 (CH=CHC(O)OCH3), 51.8 (NCHC(O)OCH3), 53.4 
(NCH2CH2), 54.9 (NCH2-CH=CH), 65.1 (CHCO), 122.6 (CH2CH=CH), 145.2 (CH2CH=CH), 
166.5 (CH=CHCO), 174.1 (NCHCO). max (thin film, cm-1), 2951 (C-H), 1732 (Ester CO2), 
1435 (Alkene C-H), 1195 and 1167 (C-N); m/z (ES+) calculated for C11H17NO4 [M+H]
+; 
228.1230. found 228.1237. 
 
2.4.21 N-(Pent-2-enyl)-L-proline methyl ester 145d 
 
 
 
 
Pent-2-en-1-ol (1.15 g, 1.38 mL, 13.3 mmol, 1.1 eq) was taken up in Et2O (15 mL) and 
cooled to 0 ˚C. Phosphorus tribromide (1.80 g, 0.63 mL, 6.66 mmol, 0.55 eq) was then 
added dropwise and allowed to stir at room temperature for 18h. On completion the 
reaction was quenched with H2O and extracted with Et2O (3 x 20 mL). The organic layers 
were combined, dried over Na2SO4, filtered and concentrated in vacuo. Following mono 
N-allylation procedure from the resulting oil, L-proline methyl ester hydrochloride 
(2.00g, 12.1 mmol, 1.0 eq) and triethylamine (2.47 g, 3.40 mL, 24.2 mmol, 2.0 eq) N-
(Pent-2-enyl)-L-proline methyl ester was obtained as a pale yellow oil. (1.31 g, 6.66 
mmol, 55%) 
 H (400 MHz, CDCl3), 0.97 (3H, t, J = 7.5 Hz, CH2CH3), 1.77-1.82 (1H, m, NCHCHAHB), 
1.88-1.95 (2H, m, NCHCHAHB + NCH2CH
AHB), 1.99-2.06 (2H, m, CH2CH3), 2.09-2.16 
(1H, m, NCH2CH
AHB), 2.34 (1H, app q, J = 9.0 Hz, NCHAHBCH2), 3.07 – 3.22 (4H, m, 
NCHAHBCH2, NCH2, CHCO), 3.71 (3H, s, OCH3), 5.52 (1H, ddt, J = 1.0, J = 6.5, J = 15.5 
Hz, NCH2CH=CH), 5.65 (1H, dt, J = 6.0, J = 15.5 Hz, NCH2CH=CH).C (100 MHz, CDCl3), 
13.4 (CH2CH3), 23.1 (NCHCH2), 25.3 (CH2CH3), 29.6 (NCH2CH2), 51.8 (OCH3), 53.6 
(NCH2CH2), 57.1 (NCH2CH), 65.3 (CHCO), 125.5 (NCH2CH=CH), 135.8 (NCH2CH=CH2), 
174.9 (CO). max (thin film, cm-1), 2951 (C-H), 1732 (Ester CO2), 1435 (Alkene C-H), 
1195 and 1167 (C-N); m/z (ES+) calculated for C11H19NO2 [M+H]
+; 198.1489. found 
198.1493. 
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2.4.22 (S)-Methyl 1-((2R,3S)-2-(1,3-dioxoisoindolin-2-yl)-3-
methylpent-4-enoyl)pyrrolidine-2-carboxylate 146a 
   
 
Following general Belluš Claisen procedure from dried Yb(OTf)3 (620 mg, 1.00 mmol, 1.0 
eq), N-Crotyl-L-proline methyl ester (183 mg, 1.00 mmol, 1.0 eq), N,N-
diisopropylethylamine (258 mg, 0.35 mL, 2.00 mmol, 2.0 eq) and N-phthaloylglycyl 
chloride (335 mg, 1.50 mmol, 1.5 eq) (S)-Methyl 1-((2R,3S)-2-(1,3-dioxoisoindolin-2-
yl)-3-methylpent-4-enoyl)pyrrolidine-2-carboxylate was obtained following purification 
by column chromatography (Et2O) that yielded the two major diastereoisomers in a 
1.9:1.0 ratio as a yellow oil.  (157 mg, 0.42 mmol, 42%).   
 H (400 MHz, CDCl3), 0.99 (3H, s, J = 7.0 Hz, CHCH3), 1.83-2.21 (4H, m, NCHCHAHBCH2, 
NCH2CH
AHB), 3.50-3.80 (3H, m, NCH2CH2, CHCH3), 3.63 (2H, s, major diastereoisomer 
OCH3), 3.72 (1H, s, minor diastereoisomer OCH3), 4.43-4.54 (1H, m, NCHCH2), 4.68-
4.80 (1H, m, (CO)2NCH), 5.08-5.27 (2H, m, CH=CH2), 5.89 (1H, ddd, J = 7.5, J = 10.5, 
J = 17.5 Hz, CH=CH2), 7.75-7.77 (2H, m, Ar-H), 7.88-7.90 (2H, m, Ar-H). C (100 MHz, 
CDCl3), 16.3 (CHCH3), 25.1 (NCHCH2), 28.8 (NCH2CH2), 35.9 (CHCH=CH2), 47.1 
(NCH2CH2), 52.1 (OCH3), 56.5 ((CO)2NCH), 59.1 (NCHCH2), 116.4 (CH=CH2), 123.6 (Ar-
C), 131.4 (Quat. Ar-C), 134.3 (Ar-C), 139.6 (CH2=CH), 166.3 (CH(CO)NCH), 167.5 
(N(CO)2), 172.1 (COCH3). m/z (ES
+) calculated for C20H22O5N2 [M+H]
+; 371.1601. found 
371.1602. 
 
 
2.4.23  (S)-Methyl 1-((R)-2-(1,3-dioxoisoindolin-2-yl)-4-
methylpent-4-enoyl)pyrrolidine-2-carboxylate 146c     
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Following general Belluš Claisen procedure from dried Yb(OTf)3 (620 mg, 1.00 mmol, 1.0 
eq), N-(2-methylprop-2-en-1-yl)-L-proline methyl ester (183 mg, 1.00 mmol, 1.0 eq), 
N,N-diisopropylethylamine (258 mg, 0.35 mL, 2.00 mmol, 2.0 eq) and N-phthaloylglycyl 
chloride (335 mg, 1.50 mmol, 1.5 eq) (S)-Methyl 1-((R)-2-(1,3-dioxoisoindolin-2-yl)-4-
methylpent-4-enoyl)pyrrolidine-2-carboxylate was obtained following purification by 
column chromatography yielding the two diastereoisomers in a 3.0:1 ratio as a yellow 
oil.  (182 mg, 0.49 mmol, 49%). On standing the product solidified to give a yellow solid 
mp = 146-148 ˚C. 
 H (400 MHz, CDCl3), 1.77 (3H, s, CCH3), 1.77-2.25 (4H, m, NCHCHAHB, NCH2CHAHB), 
2.64-2.72 (1H, m, CCHAHB), 3.19-3.45 (2H, m, NCHAHBCH2, CCH
AHB), 3.58-3.62 (1H, m, 
NCHAHBCH2), 3.69 (2.2H, s, major diastereoisomer OCH3), 3.74 (0.8H, s, minor 
diastereoisomer OCH3), 4.50-5.56 (1H, m, CHCONCH), 4.65 (1H, s, CH=CH2 cis), 4.69 
(1H, s, CH=CH2 trans), 5.16 (1H, dt, J = 3.5, J = 14.5 Hz, (CO)2NCH), 7.73-7.74 (2H, 
m, Ar-H), 7.83-7.87 (2H, m, Ar-H). C (100 MHz, CDCl3), (major diastereoisomer), 21.9 
(CCH3), 25.3 (NCHCH2CH2), 28.8 (NCH2CH2), 36.5 (CH2C=CH2), 47.0 (NCH2CH2), 50.5 
((CO)2NCH), 52.2 (OCH3), 59.7 (CONCHCO), 114.4 (C=CH2), 123.6 (Ar-C), 131.6 (Quat. 
Ar-C), 134.1 (Ar-C), 141.1 (CH2=C), 167.3 (CH(CO)NCH), 167.6 (N(CO)2), 172.1 
(COCH3), (minor diastereoisomer), 22.0 (CCH3), 25.0 (NCHCH2CH2), 28.7 (NCH2CH2), 
36.3 (CH2C=CH2), 47.9 (NCH2CH2), 50.8 ((CO)2NCH), 52.3 (OCH3), 59.4 (CONCHCO), 
114.2 (C=CH2), 123.5 (Ar-C), 131.5 (Quat. Ar-C), 134.2 (Ar-C), 141.2 (CH2=C), 167.2 
(CH(CO)NCH), 167.4 (N(CO)2), 172.6 (COCH3). max (thin film, cm-1), 2973 (C-H), 1711 
(Ester CO2), 1655 (Amide); m/z (ES
+) calculated for C20H22O5N2 [M+H]
+; 371.1601. 
found 371.1602. 
 
2.4.24  (S)-Methyl 1-((R-2-(1,3-dioxoisoindolin-2-yl)-3,3-
dimethylpent-4-enoyl)pyrrolidine-2-carboxylate 146b       
 
 
   
 
 
Following general Belluš Claisen procedure from dried Yb(OTf)3 (620 mg, 1.00 mmol, 1.0 
eq), N-(3-methylbut-2-enyl)-L-proline methyl ester (197 mg, 1.00 mmol, 1.0 eq), N,N-
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diisopropylethylamine (258 mg, 0.35 mL, 2.00 mmol, 2.0 eq) and N-phthaloylglycyl 
chloride (335 mg, 1.50 mmol, 1.5 eq) (S)-Methyl 1-((R-2-(1,3-dioxoisoindolin-2-yl)-3,3-
dimethylpent-4-enoyl)pyrrolidine-2-carboxylate was obtained following purification by 
column chromatography (diethyl ether) yielding the two diastereoisomers in a 1.1:1 
ratio as a yellow oil that solidified on standing.  (155 mg, 0.40 mmol, 40%) mp = 142-
145 ˚C. 
 H (400 MHz, CDCl3), 1.27 (3H, s, CCH3), 1.28 (3H, s, CCH3), 1.76-2.22 (4H, m, 
NCHCHAHB, NCH2CH
AHB), 2.83-3.06 (1H, m, NCHAHBCH2), 3.46-3.61 ((1H, m, 
NCHAHBCH2), 3.70 (1.6H, s, major diastereoisomer OCH3), 3.73 (1.4H, s, minor 
diastereoisomer OCH3), 4.44-4.59 (1H, m, NCHCH2), 4.78 (1H, s, (CO)2NCH), 4.94-5.00 
(2H, m, CH=CH2), 6.27-6.36 (1H, m, CH=CH2), 7.74 -7.78 (2H, m, Ar-H), 7.84-7.91 
(2H, m, Ar-H). C (100 MHz, CDCl3), (major diastereoisomer), 24.5 (CCH3), 25.2 (CCH3), 
25.2 (NCHCH2), 28.6 (NCH2CH2), 42.3 (C(CH3)2), 46.9 (NCH2CH2), 52.2 (OCH3), 58.1 
(NCHCH2), 59.4 ((CO)2NCH), 112.3 (CH=CH2), 123.7 (Ar-C), 131.1 (Quat. Ar-C), 134.4 
(Ar-C), 145.5 (CH2=CH), 165.2 (CH(CO)NCH), 167.6 (N(CO)2), 172.2 (COCH3), (minor 
diastereoisomer), 24.1 (CCH3), 24.9 (CCH3), 24.9 (NCHCH2), 28.6 (NCH2CH2), 42.4 
(C(CH3)2), 46.9 (NCH2CH2), 58.4 (NCHCH2), 59.4 ((CO)2NCH), 112.2 (CH=CH2), 123.7 
(Ar-C), 131.3 (Quat. Ar-C), 134.4 (Ar-C), 145.4 (CH2=CH), 165.9 (N(CO)2), 172.7 
(COCH3). max (thin film, cm-1), 2980 (C-H), 1388 (C-H); m/z (ES+) calculated for 
C21H24O5N2 [M+H]
+; 385.1758 found 385.1760. 
 
2.4.25  (S)-Methyl 1-((2S,3S)-2-(1,3-dioxoisoindolin-2-yl)-3-
phenylpent-4-enoyl)pyrrolidine-2-carboxylate 147e 
 
   
 
Following general Belluš Claisen procedure from dried Yb(OTf)3 (620 mg, 1.00 mmol, 1.0 
eq), N-Cinnamyl-L-proline methyl ester (245 mg, 1.00 mmol, 1.0 eq), N,N-
diisopropylethylamine (258 mg, 0.35 mL, 2.00 mmol, 2.0 eq) and N-phthaloylglycyl 
chloride (335 mg, 1.50 mmol, 1.5 eq) (S)-Methyl 1-((2S,3S)-2-(1,3-dioxoisoindolin-2-
yl)-3-phenylpent-4-enoyl)pyrrolidine-2-carboxylate was obtained following purification 
by column chromatography (diethyl ether) yielding the two diastereoisomers in a 1.1:1 
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ratio as a colourless oil.  (222 mg, 0.51 mmol, 51%). A second column managed to 
isolate a sample of the minor diastereoisomer in a 3:1 ratio. 
 H (400 MHz, CDCl3), 1.83-2.21 (4H, m, NCHCHAHBCH2, NCH2CHAHB), 3.49-3.56 (1H, m, 
NCHAHBCH2), 3.68-3.74 (1H, m, NCH
AHBCH2), 3.64 (3H, s, major diastereoisomer OCH3), 
3.74 (3H, s, minor diastereoisomer OCH3), 4.57 (1H, dd, J = 5.5, J = 8.5 Hz, NCHCH2), 
4.96 (1H, dd, J = 7.5, J = 11.0 Hz, CHCH=CH2), 5.15-5.30 (3H, m, (CO)2NCH, CH=CH2), 
6.06 (1H, ddd, J = 7.5, J = 10.5, J = 17.5 Hz, CH=CH2), 7.60 (2H, dd, J = 3.0, J = 5.5 
Hz, Ar-H), 7.68 (2H, dd, J = 3.0, J = 5.5 Hz, Ar-H). C (100 MHz, CDCl3), 25.2 (NCHCH2), 
28.9 (NCH2CH2), 47.2 (NCH2CH2), 48.0 (CHCH=CH2), 52.2 (OCH3), 54.6 ((CO)2NCH), 
59.3 (NCHCH2), 117.7 (CH=CH2), 123.3 (Ar-C), 126.9 (Ar-C), 128.5 (Ar-C), 128.6 (Ar-
C), 131.1 (Quat. Ar-C), 133.9 (Ar-C), 137.9 (CH2=CH), 139.0 (Quat, Ar-C), 165.9 
(CH(CO)NCH), 167.1 (N(CO)2), 172.1 (COCH3). max (thin film, cm-1), 2979 (C-H), 1716 
(Ester CO2); m/z (ES
+) calculated for C25H24O5N2 [M+H]
+; 433.1758. found 433.1760. 
 
2.4.26 (S)-Methyl 1-((2R,3S)-2-(1,3-dioxoisoindolin-2-yl)-3-
(methoxycarbonyl)pent-4-enoyl)pyrrolidine-2-carboxylate 146f 
    
 
Following general Belluš Claisen procedure from dried Yb(OTf)3 (620 mg, 1.00 mmol, 1.0 
eq), N-(4-methoxy-4-oxobut-2-en-1-yl)-L-proline methyl ester (227 mg, 1.00 mmol, 1.0 
eq), N,N-diisopropylethylamine (258 mg, 0.35 mL, 2.00 mmol, 2.0 eq) and N-
phthaloylglycyl chloride (335 mg, 1.50 mmol, 1.5 eq) (S)-Methyl 1-((2R,3S)-2-(1,3-
dioxoisoindolin-2-yl)-3-(methoxycarbonyl)pent-4-enoyl)pyrrolidine-2-carboxylate was 
obtained as a viscous oil. Purification by column chromatography (diethyl ether) yielded 
the two diastereoisomers in a 1.1:1 ratio as a yellow oil.  (194 mg, 0.47 mmol, 47%). 
 H (400 MHz, CDCl3), 1.84-2.12 (4H, m, NCHCHAHBCH2, NCH2CHAHB), 3.58 (3H, s, OCH3), 
3.65 (3H, s, OCH3), 4.45-4.61 (2H, m, (CO)2NCH, CONCHCO), 5.24-5.38 (2H, m, 
CH2=CHCH + CH=CH2), 5.99 (1H, ddd, J = 9.0, J = 10.0, J = 17.0 Hz, CH=CH2), 7.74 
(2H, dd, J = 3.0, J = 5.5 Hz, Ar-H), 7.87 (2H, dd, J = 3.0, J = 5.5 Hz, Ar-H). C (100 
MHz, CDCl3), 25.1 (NCHCH2), 28.9 (NCH2CH2), 47.2 (NCH2CH2), 48.9 (NCH), 52.2 
(OCH3), 52.3 (OCH3), 53.0 (CH2=CHCH), 59.3 (NCH), 121.1 (CH=CH2), 123.7 (Ar-C), 
131.4 (Quat. Ar-C), 131.9 (CH2=CH), 134.3 (Ar-C), 165.1 (CH(CO)NCH), 167.0 
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(N(CO)2), 171.6 (COCH3), 171.9 (COCH3); max (thin film, cm-1), 2980 (C-H), 1717 (Ester 
CO2), 1657 (Amide); m/z (ES
+) calculated for C21H22O7N2 [M+H]
+; 415.1500. found 
415.1500. 
 
2.4.27  (S)-Methyl 1-((2S,3R)-2-(1,3-dioxoisoindolin-2-yl)-3-
ethylpent-4-enoyl)pyrrolidine-2-carboxylate 147d 
 
   
 
Following general Belluš Claisen procedure from dried  Yb(OTf)3 (620 mg, 1.00 mmol, 
1.0 eq), N-(pent-2-enyl)-L-proline methyl ester (197 mg, 1.00 mmol, 1.0 eq), N,N-
diisopropylethylamine (258 mg, 0.35 mL, 2.00 mmol, 2.0 eq) and N-phthaloylglycyl 
chloride (335 mg, 1.50 mmol, 1.5 eq) (S)-Methyl 1-((2S,3R)-2-(1,3-dioxoisoindolin-2-
yl)-3-ethylpent-4-enoyl)pyrrolidine-2-carboxylate was obtained as a viscous oil. 
Purification by column chromatography (diethyl ether) yielded the two major 
diastereoisomers in a 3.5:1.0 ratio as a yellow oil.  (271 mg, 0.70 mmol, 70%). 
Recrystallization from diisopropylether/IPA gave an isolated sample as a pale colourless 
solid of the minor diastereomer. mp = 135-140 ˚C. 
 
 H (400 MHz, CDCl3), 0.87 (3H, t, J = 7.5 Hz, CH2CH3), 1.21-1.32 (1H, m, CHAHBCH3), 
1.51-1.57 (1H, m, CHAHBCH3), 1.87-1.98 (2H, m, NCHCH
AHBCH2, NCH2CH
AHB), 2.01-2.14 
(2H, m, NCHCHAHBCH2, NCH2CH
AHB), 3.46-3.54 (1H, m, CHCH=CH2), 3.61-3.75 (2H, m, 
NCHAHBCH2), 3.69 (2.3H, s, major diastereoisomer OCH3), 3.70 (0.7H, s, minor 
diastereoisomer OCH3), 4.42 (1H, dd, J = 4.0, J = 8.0 Hz, NCHCH2), 4.86 (1H, d, J = 
10.0 Hz, (CO)2NCH), 5.22-5.27 (2H, m, CH=CH2), 5.69-5.78 (1H, m, CH=CH2), 7.73 
(2H, dd, J = 3.0, J = 5.5 Hz, Ar-H), 7.85 (2H, dd, J = 3.0, J = 5.5 Hz, Ar-H). C (100 
MHz, CDCl3), 11.1 (CH2CH3), 23.4 (CH2CH3), 24.9 (NCHCH2), 29.0 (NCH2CH2), 43.9 
(CHCH=CH2), 47.2 (NCH2CH2), 52.0 (OCH3), 55.9 ((CO)2NCH), 59.3 (NCHCH2), 119.0 
(CH=CH2), 123.5 (Ar-C), 131.6 (Quat. Ar-C), 134.2 (Ar-C), 136.5 (CH2=CH), 167.1 
(CH(CO)NCH), 168.0 (N(CO)2), 172.3 (COCH3). m/z (ES
+) calculated for C21H24O5N2 
[M+H]+; 385.1758. found 385.1758. 
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2.4.28 Methyl (2S)-2-(3-(1,3-dioxoisoindolin-2-yl)-2-oxo-2,3,4,7-
tetrahydro-1H-azepin-1-yl)propanoate 159 
 
Grubbs second generation catalyst (229 mg, 0.027 mmol, 0.1 eq) in DCM (2.5 mL) was 
added to a solution of (S)-Methyl 2-(N-allyl-2-(1,3-dioxoisoindolin-2-yl)pent-4-
enamido)propanoate (100 mg, 0.27 mmol, 1.0 eq) in DCM (2.5 mL). The reaction was 
allowed to stir at room temperature until consumption of starting material as monitored 
by TLC. The reaction mixture was then concentrated in vacuo and purified by column 
chromatography (diethyl ether) to give the product as a mixture of diastereoisomers (75 
mg, 0.24 mmol, 87%). 
 H (400 MHz, CDCl3), 1.17 (0.9H, app t, J = 7.0 Hz, Minor CHCH3), 1.33 (2.1H, app t, J 
= 7.5 Hz, Major CHCH3), 2.44-2.48 (1H, m, CHCH
AHB), 3.43-3.57 (1H, m, NCH
AHB), 3.61 
(3H, s, OCH3), 3.62-3.73 (1H, m, CHCH
AHB), 3.30-3.34 (0.3H, m, Minor NCHAHB), 4.38-
4.42 (0.7H, m, Major NCHAHB), 5.20 (0.3H, q, J = 7.0 Hz, Minor CHCH3), 5.52 (0.7H, q, J 
= 7.5 Hz, Major CHCH3), 5.47 (0.3H, dd, J = 3.0, J = 13.5 Hz, Minor NCH), 5.57 (0.7H, 
dd, J = 3.0, J = 13.5 Hz, Major NCH) 5.73-5.85 (2H, m, CH=CH), 7.63-7.65 (2H, m, Ar-
H), 7.77-7.79 (2H, m, Ar-H). C (100 MHz, CDCl3), (Major diastereoisomer), 14.4 
(CHCH3), 28.7 (CHCH2), 40.8 (NCH2), 50.1 (CHCH2), 51.3 (OCH3), 51.6 (CHCH3), 123.4 
(CH=CH), 122.4 (Ar-C), 128.1 (Quat. Ar-C), 129.0 (CH=CH), 133.0 (Ar-C), 167.2 
(N(CO)2), 169.2 (CH(CO)NCH), 171.0 (COCH3), (Minor diastereoisomer), 13.9 (CHCH3), 
28.3 (CHCH2), 41.4 (NCH2), 50.3 (CHCH2), 51.2 (OCH3), 52.2 (CHCH3), 123.0 (CH=CH), 
122.4 (Ar-C), 128.1 (Quat. Ar-C), 130.9 (CH=CH), 133.0 (Ar-C), 167.2 (N(CO)2), 169.0 
(CH(CO)NCH), 171.0 (COCH3). max (thin film, cm-1), 2952 (C-H), 1713 (Ester CO2), 1660 
(Amide); m/z (ES+) calculated for C18H18O5N2 [M+H]
+; 343.1288. found 343.1296. 
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